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ABSTRACT OF DISSERTATION

A NOVEL ROLE FOR NEUROTENSIN IN REGULATION
OF STEM CELL FUNCTION IN THE SMALL INTESTINE
Neurotensin (NT) is a nutrient-regulated gut hormone that plays important roles in lipid
absorption, obesity, metabolic disorders, and normal and neoplastic growth in the intestine.
In this study, we 1) elucidate the mechanisms regulating NT release from endocrine cells,
2) examine the role of NT on proliferation and stem cell function in the small intestine and
3) define the effects of NT on colorectal cancer stem cells. We report that NT release from
endocrine cells is enhanced by the MAPK scaffold protein Kinase Suppressor of Ras 1
(KSR1) and the exocyst complex component 70 (Exo70). Moreover, free fatty acid
stimulated release of NT is attenuated by inhibition of KSR1, MEK, ERK1/2, and Exo70,
indicating these proteins as possible therapeutic targets for modulating the negative effects
of NT on lipid absorption, obesity, and metabolic dysfunction.
Functionally, we show that NT plays an evolutionarily conserved role in
maintenance of intestinal stem cells during nutritional stress. NT is required for the
induction of WNT/β-catenin signaling and ISC-specific gene expression during fasting and
promotes intestinal stem cell self-renewal. In the murine small intestine, loss of NT impairs
crypt progenitor cell proliferation via downregulation of ERK1/2 signaling, cyclin D1
expression, and cell cycle related gene expression programs. Loss of NT impairs intestinal
stem cell-specific gene expression and intestinal stem cell function after fasting, whereas
NT overexpression prevents intestinal stem cell depletion in the midgut of Drosophila fed
a nutrient-reduced diet.
We extend these findings to reveal a similar role for NT in regulation of stem cell
function in colorectal cancer. NT enhances WNT/β-catenin signaling and cancer stem cell
self-renewal in the human colon carcinoma cell line HCT116 and in intestinal tumor
organoids derived from APC mutant models of colorectal cancer. Mechanistically, we
show that NT induces phosphorylation of LRP6 in an ERK1/2 dependent manner in
colorectal cancer cells and intestinal tumor organoids, indicating that NT promotes
WNT/β-catenin signaling via activation of the ERK1/2 signaling pathway. In contrast, loss
of NT impairs cancer stem cell function in tumor organoids derived from APCmin/NT-/-

mice, and our preliminary findings indicate that NT-deficiency significantly increases
lifespan in APC mutant mice.
Collectively, the studies within this dissertation identify NT as a positive regulator
of normal and neoplastic growth within the small intestine through regulation of stem cell
function and activation of the WNT/β-catenin pathway and identify potential therapeutic
targets for modulating the effects of NT in the small intestine.
KEYWORDS: Neurotensin, Gut Hormone, Intestinal Stem Cell, Cancer Stem Cell,
WNT/β-catenin Signaling, ERK1/2 Signaling
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CHAPTER 1: INTRODUCTION
1.1 Signaling Pathways Regulating Intestinal Homeostasis
1.1.1 Mechanisms of Proliferation and Differentiation
The intestinal epithelium is the most vigorously self-renewing mammalian tissue,
turning over every 3-5 days (1, 2). This self-renewal process is maintained by a population
of intestinal stem cells (ISCs) located at the base of intestinal crypts (3). These actively
cycling ISCs are highly proliferative and metabolically active and contribute to intestinal
epithelial homeostasis (4). During homeostatic self-renewal, ISCs give rise to progenitor
cells that proliferate and migrate toward the villus tip, eventually differentiating into one
of the mature intestinal cell types (2). These major cell types include absorptive
(enterocytes) or secretory (goblet, Paneth, enteroendocrine) cell lineages that mediate the
diverse functions of the small intestine, including nutrient absorption, digestion, and
mucosal barrier function (2, 4, 5).
ISC proliferation and subsequent differentiation is controlled by numerous
signaling pathways, including WNT/b-catenin, Notch, and bone morphogenic protein
(BMP), signaling (Fig 1.1) (4). WNT/b-catenin signaling at the base of the intestinal crypts
is required for ISC proliferation and self-renewal, while decreasing levels of WNT/bcatenin signaling toward the villus enable progenitor cell differentiation into one of the
mature intestinal epithelial cell types (6-8). Proliferation of the active ISC population
located at the crypt base is regulated in large part by WNT/b-catenin signaling, and these
ISCs are identified by expression of the WNT-target gene leucine-rich repeat-containing
G-protein coupled receptor 5 (Lgr5) (2, 7, 9). Lgr5+ ISCs divide at the crypt base to give
rise to progenitor cells, which undergo several more rounds of division in the transit1

amplifying region as they migrate up the crypt prior to terminal differentiation (2). As
progenitor cells migrate toward the villus tip, they encounter signals that oppose WNTactivation and permit cell differentiation, such as BMP signaling (4). Other critical
pathways that regulate intestinal homeostasis include EGF/MAPK signaling, which
contributes to proliferation within intestinal crypts, and Notch signaling, which promotes
self-renewal at the crypt base and plays a critical role in cell fate determination (4). In the
mammalian small intestine, alteration of any one of these signaling pathways may perturb
crypt cell proliferation or the trajectory of progenitor cell differentiation and therefore
contribute to intestinal diseases or colorectal cancer (CRC) (2, 5, 10).

1.1.2 The WNT/b-catenin Pathway
The self-renewal properties of ISCS, and thus the whole of intestinal homeostasis,
is critically dependent on WNT/b-catenin activation at the crypt base (6). The WNT/bcatenin pathway has numerous important physiological functions, including regulation of
embryonic development, tissue homeostasis, and cell proliferation, migration, and fate
determination, among other processes (6-8, 11). The WNT/b-catenin pathway is highly
conserved and contributes to ISC function in Drosophila as well as mammals (12). The
canonical WNT-pathway is dependent on the activity of β-catenin (11). WNT signaling is
activated by WNT-ligands that cause nuclear translocation of β-catenin and activation of
WNT-target gene expression (Fig 1.2) (11). In the absence of WNT-ligands, β-catenin is
continually degraded by the actions of the β-catenin destruction complex, a protein
complex composed of the scaffold protein Axin, the tumor suppressor adenomatous
polyposis coli gene product (APC), casein kinase 1 (CK1), and glycogen synthase kinase
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3 (GSK3) (11). CKI and GSK3 phosphorylate β-catenin, resulting in its ubiquitination and
proteasomal degradation. Under these conditions, cytosolic β-catenin is continually
degraded and WNT-target gene expression is repressed (11).
The WNT/b-catenin pathway is activated by the binding of WNT-ligands to the
seven-pass transmembrane Frizzled (FZD) receptor and its co-receptor, low-density
lipoprotein receptor related protein 6 (LRP6) or LRP5, which results in the formation of a
FZD:LRP co-receptor complex (8, 11, 13). Upon formation of this complex, the
scaffolding protein Dishevelled (DVL) binds to FZD, leading to phosphorylation of LRP6
on Ser1490 and recruitment of Axin to the receptor complex. Translocation of Axin to the
FZD:LRP:DVL complex disrupts the β-catenin destruction complex, reducing the ability
of CKI and GSK3 to phosphorylate β-catenin (11, 13, 14). As a result, non-phosphorylated
(active) β-catenin accumulates and travels to the nucleus, where it interacts with TCF/LEF
transcription factors and activates expression of WNT-target genes that regulate a number
of proliferative and oncogenic functions (8). Activation of WNT/b-catenin signaling in the
ISC niche is mediated by WNT-ligands secreted from Paneth cells and from subepithelial
fibroblasts located beneath intestinal crypts (7). However, Paneth cells are dispersible for
normal ISC function in vivo, indicating that subepithelial fibroblasts are the critical source
of WNT ligands in the small intestine (4).

1.1.3 The MAPK Signaling Pathway
EGF/MAPK signaling is also implicated in directing the proliferation and
differentiation of ISCs and crypt progenitor cells (2, 4). EGF, through binding to EGF
receptor (EGFR), stimulates the MAPK pathway by activating the MAP kinase kinase

3

kinase (MAPKKK) Raf (Fig 1.3) (15). Activated Raf phosphorylates the MAP kinase
kinases (MAPKKs) MEK1 and MEK2 (MEK1/2), which phosphorylate and activate
ERK1/2 (16). Activated ERK1/2 can phosphorylate many different cytosolic substrates or
travel to the nucleus, where it activates transcription of genes promoting cell cycle
progression, DNA synthesis, and cell proliferation (15). Signaling of these MAPK complex
proteins is potentiated by molecular scaffold proteins, including Kinase Suppressor of Ras
1 (KSR1). The scaffolding function of KSR1 serves to coordinate the spatial localization
of the Raf/MEK/ERK proteins and enhances ERK1/2 activation (17). Disruption of MAPK
signaling alters proliferation and WNT/b-catenin signaling in intestinal crypts, yet its role
in intestinal homeostasis appears complex (18, 19). ERK1/2 are central regulators of cell
cycle progression, and their activation has been previously shown necessary for
proliferation of intestinal epithelial cells and development of the intestinal epithelium (15,
20, 21). However, recent work has revealed a more varied role for ERK1/2 signaling in
intestinal crypts. In some models, ERK1/2 inactivation has been shown to enhance crypt
cell proliferation and promote WNT/b-catenin signaling during development, suggesting
complex crosstalk between these pathways under certain cellular contexts (22).
Nonetheless, numerous studies identify a positive role for ERK1/2 signaling in regulation
of intestinal epithelial cell growth and proliferation of crypt progenitor cells, and EGF is a
necessary component of intestinal organoid culture media to sustain optimal organoid
proliferation and maturation (2, 20, 23).
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1.1.4 Nutritional Regulation of Intestinal Homeostasis
Dietary signals are key regulators of intestinal homeostasis (24). ISCs integrate
diet-induced physiological signals to direct intestinal cell proliferation and differentiation
(24). Nutrient-responsive pathways such as AMPK, PPARd, and mTOR signaling regulate
ISC function and proliferation in response to diet (3). In high-fat diet (HFD)-induced
obesity mouse models, excess dietary fat intake promotes stemness and tumorigenicity of
ISCs and progenitors by activating WNT/b-catenin signaling (25). However, long-term
calorie restriction also enhances intestinal proliferation through modulation of various
nutrient-responsive signaling pathways, including mTOR and AMPK signaling (26). In
contrast, nutrient deprivation diminishes intestinal proliferation and induces intestinal
atrophy, while boosting ISC function by enhancing fatty acid oxidation (FAO) (27). Under
conditions of acute or prolonged absence of enteral nutrients, the intestinal epithelium is
remodeled in the process of intestinal adaptation (28). Proliferation in intestinal crypts is
diminished, apoptosis increases in the villi and crypts, and ISC function is altered (27-29).
Molecules that enhance crypt proliferation or ISC function or in other ways mitigate the
impacts of enteral nutrient deprivation may be promising therapeutic targets for the
treatment of intestinal diseases characterized by altered intestinal homeostasis.
1.2 Mechanisms and Consequences of NT Release
1.2.1 NT Localization and Secretion
Neurotensin (NT) is a 13 amino acid peptide (pGlu-Leu-Tyr-Glu-Asn-Lys-ProArg-Arg-Pro-Tyr-Ile-Leu) found in the central nervous system (CNS) and gastrointestinal
tract (30, 31). In the brain, NT is located in nerve terminal fibers and cells, while within
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the intestine NT is localized to enteroendocrine (EE) cells (32, 33). Though EE cells have
historically been categorized based on the peptide they secrete, such that NT-secreting EE
cells are designated as “N-cells,” many recent studies have highlighted extensive overlap
between peptides secreted from a single EE cell type. For instance, activation of BMP
signaling in glucagon-like peptide-1 (GLP-1) releasing “L-cells” has been shown to induce
a switch in peptide secretion from GLP-1 to NT and peptide YY (PYY) (34). In the same
study, high levels of BMP signaling in the villus region induced expression of Secretin
(sct) in most EE cells (34, 35). Thus, multiple EE cell subtypes may be capable of releasing
NT under various conditions.
Release of NT from EE cells occurs via the regulated secretory pathway (36). After
proteolytic processing of the NT precurser fragment (pro-NT), NT is transported from the
trans Golgi network to secretory vesicles, where it is stored until extracellular stimuli
trigger NT release (36-38). Ingestion of dietary fats is the strongest extracellular stimulus
regulating NT release (36), triggering exocytosis of NT-containing secretory vesicles (37,
38). Once released, NT regulates many physiological functions, including analgesia and
neurotransmitter signaling in the CNS and cell proliferation and lipid absorption in the GI
tract (31, 39-42). ERK1/2 and free fatty acids (FFAs) are known to stimulate NT secretion,
yet the precise mechanisms contributing to NT exocytosis are unclear (43, 44). Functions
of NT release in the small intestine include regulation of cell proliferation, FFA absorption,
glucose homeostasis, and tumorigenesis (45-47). Thus, NT signaling is an attractive
therapeutic target the treatment of metabolic disorders and various cancers. However, a
more thorough understanding of the signaling events regulating NT release from endocrine
cells is necessary to determine the full therapeutic potential of NT or NT-pathway targets.
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1.2.2 NT/NTR1 Signaling
The effects of NT are mediated through three NT receptors (NTRs) (Fig 1.4). The
high affinity NTR1 and low affinity NTR2 are G-protein-coupled receptors, while NTR3
is a single-pass transmembrane domain identical to the intracellular sorting receptor sortilin
(30). NTR1 is widely expressed in the CNS and various cancer cells (30, 39). NTR1 exerts
many of the effects of NT in the CNS, including activation of dopamine and glutaminergic
signaling (31, 39). In the CNS, NT is localized to presynaptic and postsynaptic vesicles
and acts as a primary neurotransmitter (31, 39). NT-inhibition of dopamine D2
autoreceptors induces dopamine signaling, mimicking D2 receptor antagonists (31, 39).
NTSR2 is 64% homologous to NTR1 but has a low-affinity for NT binding (48). NTSR2
is expressed predominantly in the CNS in areas related to pain perception (39).
Administration of NT into the periaqueductal gray (PAG) and the rostral ventrolateral
medulla (RVLM) induces analgesia, and inhibition of NTR2 but not NTR1 blocks this
effect (39). NTR3/sortilin is widely expressed and not NT-specific (48, 49).
In the gastrointestinal tract, NTR1 mRNA is undetectable in most normal tissues
but highly upregulated in various gastrointestinal cancer cells (50). In contrast, NTR2 is
expressed in the gastric mucosa and EE cells of the small and large intestine but rarely
detected in human tumors (50). NTR3 is broadly expressed in normal and cancer cells,
including cells of the gastrointestinal tract, and may serve as a co-receptor to facilitate
NT/NTR1 signaling (50, 51). Most studies indicate that the effects of NT are predominantly
mediated by NTR1 (50). Precise localization of NTR1 expression in the small intestine is
debated. Single-cell RNA-seq experiments fail to detect NTR1 expression in any intestinal
epithelial cell populations (52), suggesting that other intestinal cell types, such as
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macrophages, enteric neurons, or subepithelial cells may mediate the effects of NT in the
small intestine. Interestingly, single-cell sequencing does detect NT in some putative ISCs
(52), and in the colon, NTR1 expression is highest at the crypt base, near the ISC niche
(53).

1.2.3 NT Regulation of MAPK Signaling
NT/NTR1 signaling leads to activation of signal transduction pathways involved in
cell proliferation and survival, including PI3K/AKT, MAPK/ERK, GSK3b, and NFκB
signaling (Fig 1.5) (31, 44, 54, 55). NT/NTR1 signaling activates phospholipase C (PLC)
via Gαq/11 activation, leading to increased intracellular levels of the second messengers
Inositol trisphosphate (IP3) and Phosphatidylinositol 4,5-bisphosphate (PIP2) and
activation of protein kinase C (PKC) and intracellular calcium release (50). NTR3/sortilin
activation in the brain is associated with activation of PI3K/AKT and MAPK/ERK
signaling (48). NT-induced FFA absorption is mediated by inhibition of AMPK signaling
in enterocytes (46). NT-induced activation of the MAPK/ERK pathway has been recorded
in numerous cancer cell lines and is thought to be a primary mechanism of NT-induced
cancer cell proliferation (47, 48). Upon binding to NTR1, NT activates a classic GPCR
signaling cascade that activates MAPK signaling and ERK1/2 phosphorylation (56).
Notably, Ras and ERK1/2 positively regulate NT gene expression, indicating a positive
feedback loop stimulating NT release and ERK1/2 signaling (44, 57). Like NT, EGF
signals predominantly via the MAPK pathway and is a critical ligand for maintaining
intestinal proliferation within the ISC niche (22). Whether NT plays a similar role in
maintenance of proliferation within the ISC niche is unknown.
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1.2.4 NT Crosstalk WNT/b-catenin Signaling
Several studies have identified crosstalk between NT/NTR1 signaling and
pathways involved in WNT/b-catenin signaling. In CRCs, NTR1 expression is activated
by WNT/APC signaling, and NTR1 is positively correlated with nuclear β-catenin
expression in gastric cancer (58, 59). NT has also previously been shown to contribute to
phosphorylation of GSK3b, a negative regulator of WNT activation, via PKC and AKT
signaling (60). Phosphorylation of GSK3b on Ser9 by AKT inhibits GSK3b activity, which
serves primarily to phosphorylate and sequester b-catenin (14, 61, 62). Though some have
suggested that AKT phosphorylates a pool of GSK3b that is not involved in regulation of
b-catenin, multiple studies have demonstrated AKT-mediated activation of WNT/bcatenin signaling via GSK3b inhibition (14, 61-63). NT mediates phosphorylation of
GSK3b in the human colon carcinoma cell line HCT116 (60), suggesting a possible role
for NT in regulation of WNT/b-catenin downstream of GSK3b in CRCs. Consistent with
this, NT enhanced epithelial-to-mesenchymal features and increased expression of WNT
ligands, WNT-target genes, and phosphorylated-GSK3b in hepatocellular carcinoma cells
in an NTR1-dependent manner (64). In glioblastoma cells, NT/NTR1 signaling is proposed
to activate WNT/b-catenin signaling via activation of ERK1/2 (55). The kinase activity of
ERK1/2 is known to phosphorylate LRP6 and facilitate activation of the WNT/b-catenin
pathway (65). WNT/b-catenin signaling plays an important role in tumorigenesis (11).
Disruption of WNT/b-catenin signaling is a fundamental step in the development of CRC,
and high levels of WNT-target gene expression contribute to proliferation and tumor
growth in numerous cancers (8, 66). Notably, Lgr5+ ISCs are proposed to be a CRC cell9

of-origin, and WNT-activating mutations in ISCs are known to promote intestinal
tumorigenesis (10). Therefore, defining the factors that control intestinal WNT/b-catenin
signaling and Lgr5+ ISC function is critical for understanding the mechanisms underlying
the development of CRC.

1.2.5 Physiologic Functions of NT
NT plays an important role in FFA absorption in the small intestine and contributes
to lipid metabolism and glucose homeostasis (46). Previous work from our lab has shown
that NT-deficiency reduces intestinal lipid absorption, prevents the onset of HFD-induced
obesity, and attenuates obesity-induced hepatic steatosis and insulin resistance (46). In
humans, NT is a predictive marker for the development of obesity and its comorbidities.
In human longitudinal studies, patients with high fasting plasma levels of pro-NT were
over twice as likely to develop obesity later in life as those with the lowest pro-NT levels
(46). Elevated plasma concentrations of pro-NT are also associated with insulin resistance,
metabolic disorders, and visceral adipose tissue (VAT) inflammation in obese patients (67,
68) and are predictive of the presence and severity of non-alcoholic fatty liver disease
(NAFLD) (69). Notably, both NT and HFD play an important role in the development of
certain cancers, and FFAs promote NT secretion and intestinal cancer growth (70, 71).
Given the role of NT on FFA absorption and HFD-induced obesity, NT-mediated lipid
absorption may contribute to HFD-induced tumorigenesis.
The proliferative function of NT in the gastrointestinal tract has been demonstrated
in multiple models of normal physiology and intestinal stress. NT stimulates growth of the
mammalian small intestine and colon under basal conditions and in response to nutrient-

10

deprivation and intestinal injury (45). NT increases intestinal regeneration after small
bowel resection (SBR) in rats, with more prominent effects in the proximal small intestine,
and reverses mucosal hypoplasia due to feeding a liquid elemental diet (72-74). In mouse
models of chronic intestinal inflammation, NT facilitates mucosal wound healing,
suggesting a possible therapeutic role for NT in the treatment of inflammatory bowel
disease (75). NT also has potent anti-apoptotic effects, which further contributes to its
growth-stimulating functions (76). NT attenuates intestinal epithelial cell apoptosis in
mouse models of obstructive jaundice and colitis (75, 77). Collectively, the combined
effects of NT on proliferation and apoptosis during basal and stress conditions within the
small intestine indicate that NT plays an important protective role in maintenance of
intestinal epithelial cell integrity.
Numerous other intestinal growth factors or peptides have been shown to contribute
to mucosal growth, protection, or adaptation in the mammalian small intestine (78). Like
NT, glucagon-like peptide 2 (GLP-2), insulin-like growth factor-1 (IGF-1), PYY, and
gastrin releasing peptide (GRP) stimulate intestinal adaptation following SBR (78).
Ghrelin attenuates ISC damage and promotes epithelial cell proliferation following
irradiation (79). The GLP-2 analog teduglutide is approved for the treatment of patients
receiving total parenteral nutrition (TPN) as a result of clinical and preclinical studies
demonstrating that GLP-2 promotes growth, proliferation, and maintenance of the
intestinal epithelium (80-82). Interestingly, the enterotrophic effects of GLP-2 are
enhanced by the presence of NT (83). However, the extent to which NT contributes to
intestinal proliferation or ISC function during nutritional stress has not been fully
investigated. In order to determine the full therapeutic potential of NT on intestinal
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adaptation to nutrient state or gastrointestinal disorders, the mechanisms and consequences
of NT release in the small intestine must be more fully characterized.

1.2.6 Role of NT in Cancer Stem Cell Function
In addition to the pro-growth effects of NT in the normal intestinal mucosa, NT is
also known to have oncogenic effects in various cancer types, including gastric, pancreatic,
hepatic, colorectal, and breast cancer (84). NT and NTR1 expression are upregulated in
numerous cancer cells, and their high expression is associated with poor disease prognosis
(58). In addition, some cancer cells secrete NT and express NTR1, leading to autocrine
activation of the growth-stimulating pathways downstream of NT/NTR1 signaling (84).
The effects of NT on NTR1-expressing cancer cells include increased proliferation,
migration, invasion, and angiogenesis (13, 30, 31). Recent studies have implicated NT in
regulation of stem-cell like properties of cancer cells, suggesting that NT may contribute
to cancer stem cell (CSC) function (85, 86). CSCs are a subpopulation of cancer cells with
stem-cell like properties, including self-renewal, differentiation, tumorigenicity, and
resistance to cancer therapy (87). NT promotes tumorigenesis and self-renewal of
hepatocellular carcinoma (HCC) stem cells, in part, via activation of the ERK1/2 signaling
(85). Likewise, NT promotes CSC function in glioblastoma cells in an EGFR-dependent
mechanism, whereas NTR1 knockdown reduces expression of glioblastoma CSC markers
(86). In CRC cells, CSCs are defined by high WNT activity, and activation of WNT/bcatenin signaling in more differentiated tumor cells restores stem-cell like function and
increases CSC clonogenicity, indicating that WNT/b-catenin is an important regulator of
CSC function in CRC (88).
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1.3 Goals and Hypotheses For Dissertation
The known functions of NT converge on multiple important physiological and
pathological processes. NT is associated with lipid absorption, metabolic disorders, HFDobesity, and oncogenic functions in a variety cancers, suggesting that control of NT release
from EE cells may be therapeutically beneficial (42, 48, 89). Yet NT also exerts several
protective functions on the intestinal mucosa, indicating that NT release and signaling must
be tightly controlled to maintain homeostasis (40, 41, 73, 75). Given the proliferative
actions of NT and its proposed crosstalk with multiple signaling pathways that are critical
to the maintenance of stem cell function, including ERK1/2 and WNT/b-catenin, the
primary goals of this dissertation were to 1) elucidate the mechanisms regulating NT
release from endocrine cells, 2) to determine the role of NT on proliferation and stem cell
function in the small intestine and 3) to define the effect of NT on colorectal cancer stem
cells. We investigated the functional impacts of NT using in vivo models of nutrientdeprivation, NT-deficiency/overexpression, and colorectal cancer, and explored the
mechanisms of NT release and function utilizing in vitro models of gut hormone secretion
and ex vivo intestinal organoid and tumor organoid systems. Based on the current
understanding of NT secretion and functions described here, this dissertation examines the
following hypotheses:
1) NT release from endocrine cells can be manipulated via regulation of the
ERK1/2 signaling pathway.
2) NT regulates intestinal stem cell function via activation of WNT/b-catenin
signaling.
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3) NT promotes cancer stem cell function in colorectal cancers through activation
of WNT/b-catenin signaling.
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Figure 1.1: Mechanisms regulating proliferation, differentiation, and stem cell
function in the small intestine.
Self-renewal of ISCs, located at the crypt base, is regulated by WNT, Notch, and MAPK
signaling, whereas BMP and hedgehog signaling oppose these proliferative signals in the
villus regions and enable progenitor cells to differentiate into enterocytes, enteroendocrine
(EE), Paneth, goblet, or tuft cells. WNT ligands are secreted from Paneth cells and
subepithelial fibroblasts and maintain high levels of WNT-activation in the ISC niche.
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Figure 1.2: Overview of the WNT/b-catenin signaling pathway. (Left) In the absence
of WNT-ligands, the b-catenin destruction complex, composed of GSK3, CKI, APC, and
Axin, phosphorylates b-catenin leading to its proteasomal degradation and repression of
WNT-target gene expression. Upon WNT ligand binding to Frizzled (FZD) and LRP5/6
on the plasma membrane, DVL and Axin are recruited to the plasma membrane, causing
disruption of the

b-catenin destruction complex and enabling b-catenin to enter

accumulate, enter the nucleus, and regulate WNT-target gene expression via activation of
TCF/LEF transcription factors (Adapted from Khalf et al. (90)).
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Figure 1.3: Summary of ERK/MAPK signaling. Growth factor binding to EGFR
activates

the

MAPK

signaling

pathway

(RAS-RAF-MEK-ERK),

leading

to

phosphorylation and activation of ERK1/2, which regulates transcription of genes involved
in cell proliferation, survival, and metastasis (Adapted from JJ Medicine).
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Figure 1.4: Neurotensin receptors. Neurotensin signaling is mediated by three NT
receptors (NTR1, NTR1, and NTR3). NTR1 and NTR2 are GPCRs and NTR3 is type I
receptor identical to sortilin. (Adapted from Christou et al. (47))
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Figure 1.5: Overview of NT/NTR signaling. NT binds to NTR1 alone or in complex with
NTR3 and activates PLC, PI3K/AKT, MAPK/ERK, or Rho GTPase signaling.
Downstream effectors of these pathways participate in transcription of genes that regulate
cell proliferation and survival. (Adapted from Christou et al. (47))
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CHAPTER 2: MATERIALS AND METHODS
2.1 Mice
The following mice were used for these studies: NT wild type (Nt+/+), knockout
(Nt-/-), Lgr5-EGFP-IRES-CreERT2 (Jackson Laboratory, strain name: B6.129P2Lgr5tm1(cre/ERT2)Cle/J, stock number 008875), and Lgr5-EGFP-IRES-CreERT2; Nt-/mice; APCmin;Nt+/+ and APCmin; Nt-/- mice, and APCmin/KRAS mice. All procedures were
approved by the Institutional Animal Care and Use Committee of the University of
Kentucky. Mice were maintained on a 14 h light/10 h dark cycle and provided with food
and water ad libitum (AL) unless otherwise indicated (3). For fasting studies, mice were
fasted for 48 h beginning at 9 AM with AL access to water. Body weight was measured
daily during the fasting period. Control mice were sex- and age-matched littermates fed
standard chow AL. For HFD-induced obesity studies, mice were placed on a 60% HFD or
10% LFD (catalogue no. D12492 and D12450B, respectively; Research Diets, New
Brunswick, NJ) at weaning for 22–24wks. Male and female mice aged 3-6 months were
used for all studies.
2.2 Tissue isolation and organoid culture
Crypts were isolated from the proximal two-thirds of the small intestine as
previously described (25). Briefly, the small intestine was removed, opened longitudinally,
washed with PBS, and cut into 3–5mm fragments. Fragments were incubated in cold PBS
containing 10mM EDTA for 30-60 min on ice at 4°C, followed by vortexing and filtration
through a 70 µM cell strainer. Isolated crypts were collected for RNA and protein
extraction or organoid culture. For organoid culture, crypts were embedded in growthfactor reduced Matrigel (Corning) and cultured in basal organoid media supplemented with
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EGF 40 ng/ml (Peprotech), Noggin 200 ng/ml (Peprotech), and R-spondin 500 ng/m1 (Sino
Biological). Basal organoid media contained Gibco, Advanced DMEM/F12 supplemented
with N-acetyl-L-cysteine 1 M (Sigma-Aldrich), N2 1X (Life Technologies), B27 1X (Life
Technologies), Penicillin/Streptomycin 1X (Sigma-Aldrich), HEPES 1X (Sigma-Aldrich),
and Glutamax 1X (Sigma-Aldrich). Organoids were passed every 5-7 d by mechanical
disruption with a 1 mL pipette and replated in fresh Matrigel.
For tumor isolation and tissue collection, mice were sacrificed and small intestine
and colon removed for organoid culture and immunohistochemistry. The distal one-third
of the small intestine and entire colon, excluding cecum, were fixed overnight in 10%
neutral buffered formalin for immunohistochemistry. Tumors were removed from the
proximal two-thirds of the small intestine for organoid culture as previously described.
Briefly, tumors were rinsed in cold PBS, minced, and incubated in digestion buffer
composed of DMEM-F12 supplemented with FBS, collagenase and dispase for 1h at 37°C
with agitation. Following digestion, tumor fragments were allowed to settle and
supernatant was collected and centrifuged for 3 min at 200g. The cell pellet was washed
once with ice-cold PBS and filtered through a 40uM cell strainer. Tumor cells were
embedded in Matrigel (Corning) and cultured in basal organoid media supplemented with
EGF 100 ng/ml (Peprotech). Basal organoid media contained Gibco, Advanced
DMEM/F12 supplemented with N-acetyl-L-cysteine 1 M (Sigma-Aldrich), N2 1X (Life
Technologies), B27 1X (Life Technologies), Penicillin/Streptomycin 1X (Sigma-Aldrich),
HEPES 1X (Sigma-Aldrich), and Glutamax 1X (Sigma-Aldrich). Tumor organoids were
passed every 3-5 d by incubating in TrypLE Express (Invitrogen) for 5 min at 37°C,
dissociating with a 1 mL pipette, and replating in fresh Matrigel.
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2.3 Colony formation and viability assays
For crypt colony-formation assays, freshly isolated crypts were counted and plated
in triplicate in a 48-well plate. Organoid formation was quantified 3 d after initiation of
cultures and normalized to the number of crypts plated per well at day 0. For tumor
organoid colony-formation assays, mature tumor organoids were incubated in TrypLE
Express (Invitrogen) for 5 min at 37°C and then passed through a 23G needle to achieve a
single-cell suspension. Cells were counted on a Vi Cell XR Cell Counter and 2,000 cells
were plated in triplicate in a 48-well plate. Colony formation was assessed 4-7d following
initiation of culture. HCT116 colony formation was assessed using the 3D CellTiter Glo
Viability assay according to the manufacturer’s protocol. Briefly, 7d after initiation of
tumorsphere culture, 50% of the cell culture media was removed and replaced with Cell
Titer Glo reagent, incubated at room temperature for 25 min with agitation, and luciferase
analyzed on a Varioscan Lux plate reader.
2.4 Drosophila studies
Constitutive expression of NT in gut EE was achieved by cloning the gut EE cellspecific tachykinin (TK) promoter (2.0kb) into attB-UAST lacking Gal4 binding sites
followed by insertion of full-length NT cDNA (91, 92). The resulting plasmid (TK-NT)
was inserted at the VK5 attP locus. esg-Gal4-UAS-GFP/Cyo; +/TM6B and esg-Gal4-UASGFP/Cyo; TK-NT/TM6B flies were fed standard fly food (cornmeal-yeast) or low energy
diet (LED) (93, 94). Briefly, flies (5d after emerging) were maintained on standard fly food
for an additional 5d, split into two groups, and fed either standard fly food or LED fly food
(diet composition in 100 ml media: 4 g yeast extract; 4 g sucrose; 5.2 g cornmeal; 1.5 g
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agar) for a further 5d. Midguts were dissected, fixed in 4% formaldehyde in PBS for 20min,
permeabilized

in

0.1%

Triton

X-100

in

PBS,

and

processed

for

either

immunohistochemistry using α-GFP (Clontech) primary antibody or lipid staining using
Nile Red. Fluorescence signals were acquired on an Olympus confocal microscope and
images processed with Olympus FV10-ASW Ver.3.1b. 100-700 ISCs were quantified in
the midgut of 8-15 flies per group and normalized to the area of midgut captured per image.
2.5 RNA-Seq, differential expression, and gene set enrichment analysis
Isolated RNA quality and quantity was assessed using the Agilent Bioanalyzer
2100 RNA Nano chip. RNA-Seq libraries were prepared using KAPA RNA Hyper +
RiboErase HMR (Roche). The manufacturer’s protocols were used to sequence ribosomal
RNA-depleted libraries at 1x100 single-end read on an Illumina HiSeq 2500 in rapid mode,
to an average depth of 32 million single-end reads per sample. The data was stored as
FASTQ files. Sequencing reads were trimmed and filtered using Trimmomatic (V0.39) to
remove adapters and low quality reads (95). Reads were mapped to Ensembl GRCm38
(release 100) transcripts annotation using RSEM (96). RSEM results normalization and
differential expression analysis were performed using the R package edgeR (97).
Significantly up/downregulated genes were determined as fold change >= 2 and q-value <
0.05. Gene set enrichment analysis was performed using GSEA software and the Hallmark
gene sets in the Molecular Signature Database (MSigDB) (98)
2.6 Flow cytometry
Fresh intestinal crypts or organoids were incubated in TrypLE Express (Invitrogen)
for 15 min at 37°C and then passed through a 23G needle to achieve a single-cell
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suspension (25). Cells were washed in PBS, resuspended in PBS containing 1mM EDTA,
25mM HEPES, 1% FBS, and DNAse (1 µg/ml) and filtered through a 40µm cell strainer.
Cells were labeled with CD11b-PE, CD31-PE, CD45-PE, CD133-PE and EPCAM-APC
(BioLegend) and sorted with a BD FACS Aria II SORP cell sorter (25). Lgr5-EGFP+/EpCAM+/ CD11b- CD31-CD45- CD133- cells were quantified using FlowJo (v10) software
(25). Dead cells were excluded from analysis using propidium iodide (PI) (50 µg/ml)
(Abcam) (99).
2.7 Cell culture
The BON cell line was derived from a human pancreatic carcinoid tumor and
characterized previously (100, 101). BON cells were cultured in Dulbecco's Modified
Eagle's Medium/Nutrient F-12 Ham supplemented with 5% fetal bovine serum (FBS) in
5% CO2 at 37°C. The QGP-1 cell line, derived from a pancreatic somatostatinoma (Japan
Health Sciences Foundation, Osaka, Japan), was maintained in RPMI-1640 medium
supplemented with 10% FBS (102). The human colorectal adenocarcinoma cell line HT29
and the human colon carcinoma cell line HCT116 were maintained in McCoy's 5a Medium
supplemented with 10% FBS or DMEM supplemented with 10% FBS, respectively. For
HCT116 tumorsphere formation, HCT116 cells were plated at 1,000 cells per well in ultra
low-adhesion cell culture plates and cultured in serum-free DMEM F12.
2.8 Cell treatment, transfection, and lentiviral transduction
siRNA transfections were performed using RNAiMAX (Life Technologies, Grand
Island, NY). Forty-eight h after transfection, BON and QGP-1 cells were treated with
100µM DHA in serum-free medium for 90 min. Media was collected for NT-EIA and cells
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were lysed for western blot or RNA extraction. For generation of cell lines expressing
KSR1-targeting shRNA, BON or QGP-1 cells were plated in 6-well plates (5 × 105
cells/well) in growth media containing purified non-targeting control (NTC) or KSR1targeting shRNA lentivirus. Puromycin-selection was used to select for cells stably
expressing KSR1 shRNA and knockdown efficiency was measured via western blot or
quantitative real-time PCR (qRT-PCR). For cell lines expressing ERK2 or Exo70 shRNA,
lentivirus of NTC, ERK2, or Exo70 shRNAs were co-transfected with an ectopic
packaging vector into 293T cells. At 48 to 72 h post-transfection, viral supernatants were
collected and filtered through a 0.45-μm Surfactant Free-Cellulose Acetate sterile syringe
filter. BON cells were plated in 6-well plates (5 × 105 cells/well) and incubated with the
viral supernatant for 24 h, followed by incubation with growth medium for an additional
24 h. Following stable shRNA transfection, BON cells lines were sensitized to FFA
treatment and therefore treated with 30µM DHA to reduce toxicity relative to 100µM DHA
treatment. Exo70 overexpression experiments were performed with 30µM DHA for
consistency with Exo70 shRNA experiments.
For generation of cells overexpressing KSR1 or Exo70, DNA was isolated from
MSCV-IRES-GFP, MSCV-KSR1-IRES-GFP, pEGFP-control, pECFP-N-KSR1, and
pEGFP-C3-Exo70 plasmids using the Qiagen Plasmid Miniprep Kit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions. Plasmid DNA was used to transfect BON
or QGP-1 cells using Lipofectamine LTX with PLUS Reagent. Cells were collected for
NT-EIA at 48-72 h post-transfection and overexpression measured via western blot or
qRT-PCR. ON-TARGETplus SMARTpool (KSR1) and ON-TARGETplus Non-targeting
Control Pool siRNA were from GE Dharmacon (Lafayette, CO). Non-targeting control
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shRNA and shRNA targeting KSR1, ERK2, and Exo70 in bacterial glycerol stock were
from Sigma-Aldrich. MSCV-IRES-GFP, MSCV-KSR1-IRES-GFP, pEGFP-control and
pEGFP-C3-Exo70 plasmids were from Addgene (Cambridge, MA). pECFP-N-KSR1
plasmid was from Dr. Emilia Galperin’s lab (University of Kentucky).
For NT treatment of CRC cells, cells, tumorspheres, and/or tumor organoids were
treated with NT (1-100nM as indicated) in the presence or absence of the NTR1 inhibitor
SR48692 (5-10 µM), the MEK inhibitor PD0325901 (10 nM), or the mTOR inhibitor
Rapamycin (20 nM). Adherent HCT116 and HT-29 cells were treated in serum-free
DMEM/F12 or serum-free McCoy's 5a for the indicated duration. Tumor organoids and
HCT116 tumorspheres were treated in basal organoid media or serum-free DMEM/F12,
respectively. Inhibitor treatment was performed for 30 min prior to treatment with NT.
2.9 DHA treatment and NT enzyme immunoassay (EIA)
Cells were plated in 24-well plates at a density of 15×104/cm2 and grown for 48 h
for drug treatment and transfection. DHA treatment was performed in serum-free growth
medium for 90 minutes. For treatment with PD compound, cells were pretreated with PD
compound for 30 minutes in serum-free growth medium and then treated with DHA plus
PD for an additional 90 minutes. Media were collected for NT secretion measurement using
the NT-EIA kit from Phoenix Pharmaceuticals (Belmont, CA) as described previously
(103, 104) and cells were lysed for western blotting or RNA isolation. Data obtained from
NT-EIA were normalized by protein concentration from corresponding cell lysates.
2.10 in situ hybridization
Single molecule in situ hybridization was performed using Advanced Cell
Diagnostics RNAscope 2.0 HD Detection Kit (ACD Bio) with mouse Lgr5 Mm-Lgr5 (REF
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312171). Antigen retrieval was performed for 15 min and peroxidase pretreatment
performed for 30 min. Stained sections were imaged using an Aperio ScanScope XT slide
scanner at 20x and Lgr5 expression quantified using HALO software (Indica Labs)
2.11 Immunohistochemistry
For histological analysis, the small intestine (including duodenum, jejunum and
ileum) was divided into thirds and the proximal and distal thirds fixed overnight in 10%
neutral buffered formalin, paraffin embedded, and sectioned. Antigen retrieval was
performed with Tris-EDTA buffer pH 7.8 at 95°C for 64 min (standard CC1). Staining was
performed on the Ventana Autostainer with Ki67 (Abcam 16667, 1:200 for 1 hour at 37°C).
Alcian Blue (Sigma a-5268) staining was performed manually with 1% Alcian Blue
Solution in 3% glacial acetic acid. Ventana OmniMap anti-rabbit HRP and DAB were used
for visualization per manufacturer’s instructions. Stained sections were imaged using an
Aperio ScanScope XT slide scanner at 20x and analyzed using HALO software (Indica
Labs). Ki67+ and Alcian Blue+ cells were counted in 50 crypts per section in proximal and
distal small intestine from at least 5 mice per group.
2.12 Immunofluorescence
BON cells were plated on glass coverslips (#1) in 24-well plates at a density of
20×104/cm2 and transfected with pEGFP-control and pECFP-N-KSR1 plasmid DNA using
Lipofectamine LTX with PLUS Reagent. 48 h after transfection, cells were fixed in 4%
paraformaldehyde/PBS, permeabilized with 0.3% TritonX-100/PBS, and blocked with
0.1% bovine serum albumin/PBS. NT antibody was from Abcam (Cambridge, UK). Cells
were incubated with primary antibody for 1 hour, followed by Alexa Fluor-conjugated
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secondary antibody from Invitrogen for 30 minutes. Images were observed under a Nikon
confocal microscope with 40× objective.
2.13 Organoid EdU labeling
5-Ethynyl-2′-deoxyuridine (EdU)-labeling of organoids was achieved using the
Click-iT EdU Cell Proliferation Kit for Imaging (Invitrogen) according to the
manufacturer’s instructions. EdU-positive cells were quantified using Nikon Software and
expressed as Pearson’s coefficient for colocalization between 4',6-Diamidino-2Phenylindole (DAPI) and EdU. Colocalization was measured in 15-30 organoids from 3
different mice per group.
2.14 Quantitative real-time PCR
Total RNA was isolated from cells, crypts, or organoids using the RNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions. cDNA was synthesized from equal
concentrations of total RNA using the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). qRT-PCR was performed using a TaqMan Gene Expression Master
Mix (ThermoFisher) and TaqMan probes for Ksr1, Tcf7, c-Myc, Lgr5, Ascl2, Axin2, Olfm4,
Nt, Actb, and GAPDH (ThermoFisher) according to manufacturer's protocol. Relative
mRNA expression was calculated using the comparative ΔΔCt method.
2.15 Protein preparation and western blotting
Protein preparation and western blotting were performed as previously described
(103, 105). Briefly, cells, crypts, or organoids were lysed with lysis buffer (Cell Signaling
Technology) containing 1mM phenylmethylsulfonyl fluoride (PMSF). Equal amounts of
protein were resolved on 4-12% NuPAGE BisTris gels (Invitrogen, Carlsbad, CA) and
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electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes. The
following antibodies were used for western blotting: KSR1 (LifeSpace BioSciences), GFP
(Clontech), Flag (Sigma-Aldrich), pERK (CST #9101), ERK (CST #9102), GSK3b (CST
#12456), pGSK3b (CST #9322), LRP6 (CST #3395), pLRP6 (CST #2568), AKT (#4691),
pAKT (#4058), active-b-catenin (CST #8814), total b-catenin (CST #8480), and b-actin
(Sigma Aldrich A5316). Membranes were incubated with primary antibodies overnight at
4°C followed by incubation with secondary antibodies conjugated with horseradish
peroxidase. Membranes were developed with the iBright™ FL1500 Imaging System
(Invitrogen). Band intensity was measured using iBright Analysis Software (Thermo
Fisher) using β-actin or total protein as loading controls.
2.16 Statistical analysis
All experiments were performed at least three independent times and all sample
number (n) indicates biological replicates. For colony formation assays, 3-4 wells of
organoids from 5-6 mice per group were analyzed. NT secretion values were normalized
to protein concentration of corresponding lysates. All quantitative data on qRT-PCR for
genes, western blot and immunohistochemistry for proteins, organoid labeling, and
fluorescence levels for ISC quantification were summarized using bar graphs with means
and standard deviations. Comparisons across experimental factors, which includes
combination of genotype and diet, were analyzed using one-way analysis of variance or
repeated measures linear mixed model to account of repeat samples within
mice. Adjustment for multiple pairwise comparisons was performed within the model
using the Holm’s p-value stepdown method. Assessment of model assumptions were
performed and data were log-transformed as necessary for optimal fit of the model.
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Statistical analyses were performed using the SAS system 9.4 (Cary, NC). Bioinformatics
methods for differential analysis were performed using the R package as described above.
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CHAPTER 3:
KINASE SUPPRESSOR OF RAS 1 AND EXOCYST COMPLEX COMPONENT
70 PROMOTE FATTY ACID-STIMULATED NEUROTENSIN SECRETION
THROUGH ERK1/2 SIGNALING IN HUMAN NEUROENDOCRINE CELLS1
3.1 Abstract
Neurotensin is a peptide hormone released from enteroendocrine cells in the small
intestine in response to fat ingestion. Although the mechanisms regulating neurotensin
secretion are still incompletely understood, our recent findings implicate a role for
extracellular signal–regulated kinase 1 and 2 as positive regulators of free fatty acidstimulated neurotensin secretion. Previous studies have shown that kinase suppressor of
Ras 1 acts as a molecular scaffold of the Raf/MEK/extracellular signal–regulated kinase 1
and 2 kinase cascade and regulates intensity and duration of extracellular signal–regulated
kinase 1 and 2 signaling. Here, we demonstrate that inhibition of kinase suppressor of Ras
1 attenuates neurotensin secretion and extracellular signal–regulated kinase 1 and 2
signaling in human endocrine cells. Conversely, we show that overexpression of kinase
suppressor of Ras 1 enhances neurotensin secretion and extracellular signal–regulated
kinase 1 and 2 signaling. We also show that inhibition of extracellular signal–regulated
kinase 2 and exocyst complex component 70, a mediator of secretory vesicle exocytosis,
potently inhibits basal and docosahexaenoic acid-stimulated neurotensin secretion,
whereas overexpression of exocyst complex component 70 enhances basal and
docosahexaenoic acid-stimulated neurotensin secretion. Together, our findings
1

This research was originally published in PLoS One. Rock, S., Li, X., Song, J.,
Townsend, C. M., Jr, Weiss, H. L., Rychahou, P., Gao, T., Li, J., & Evers, B. M. (2019).
Kinase suppressor of Ras 1 and Exo70 promote fatty acid-stimulated neurotensin
secretion through ERK1/2 signaling. PloS one, 14(3), e0211134.
https://doi.org/10.1371/journal.pone.0211134
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demonstrate a role for kinase suppressor of Ras 1 as a positive regulator of neurotensin
secretion from human endocrine cells and indicate that this effect is mediated by the
extracellular signal–regulated kinase 1 and 2 signaling pathway. Moreover, we reveal a
novel role for exocyst complex component 70 in regulation of neurotensin vesicle
exocytosis through its interaction with the extracellular signal–regulated kinase 1 and 2
signaling pathway.
3.2 Introduction
Obesity in the United States has reached epidemic levels, with approximately 70%
of the population overweight and over 30% of overweight individuals classified as obese
(1, 2). Cancers associated with overweight and obesity account for approximately 40% of
all diagnosed cancers in the United States (1). Excess adiposity is thought to contribute to
the development of cancer through the release of free fatty acids (FFAs) by adipose tissue,
which have been shown to promote tumorigenesis by serving as metabolic fuel for highly
proliferating cells (3-6). FFAs have also been demonstrated to regulate expression and
secretion of hormones and neuropeptides, including the gastrointestinal neuropeptide
neurotensin (NT), which is implicated in the promotion of obesity and the development of
several types of cancer (7-12).
NT is released in the small intestine in response to fat ingestion and has been
implicated in the development of metabolic disorders and many types of cancer, including
breast, pancreatic, lung, prostate, and colorectal cancer (9, 10, 13-16). NT facilitates FFA
absorption in the intestine and contributes to lipid metabolism and glucose homeostasis
(12). In mice, NT deficiency reduces intestinal fat absorption and is protective against highfat diet-induced obesity, hepatic steatosis, and insulin resistance (12). In humans, elevated

32

plasma concentrations of pro-NT (a stable NT precursor fragment produced in equimolar
amounts relative to NT) are associated with insulin resistance, obesity-associated
metabolic disorders, and visceral adipose tissue (VAT) inflammation in obese patients (13,
17). Moreover, high plasma pro-NT levels are predictive of the presence and severity of
non-alcoholic fatty liver disease (NAFLD) (18). Interestingly, both NT secretion and
cancer growth are stimulated by unsaturated FAs (7, 19). Pre-clinical and epidemiologic
studies indicate that high intake of unsaturated fatty acids increases cancer risk and
promotes cancer progression (5, 7, 19-22). We have recently shown that NT secretion from
enteroendocrine (N) cells is enhanced by common unsaturated dietary FAs, including oleic
acid, palmitoleic acid, and docosahexaenoic acid (DHA) (11). Given its intersecting role
in metabolic disorders and tumorigenesis, NT may be a potential therapeutic target for
metabolic diseases and cancer.
NT is secreted from N cells via the regulated secretory pathway (23). After
proteolytic processing of the NT precursor (pro-NT), active NT peptide is transported from
the trans Golgi network and stored in secretory vesicles until NT release is triggered by
extracellular stimuli (23-25). NT-containing secretory vesicles are then transported to the
plasma membrane and released to the cell exterior via exocytosis (24, 25). While the most
potent extracellular stimulus regulating NT release from the small intestine is fat ingestion,
the molecular mechanisms regulating FA-stimulated NT secretion are still incompletely
understood (23). We have previously demonstrated that NT gene expression is enhanced
by Ras signaling and that extracellular signal–regulated kinase 1 and 2 (ERK1/2) positively
regulate NT gene expression and FA-stimulated NT peptide secretion (11, 12, 26).
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ERK1/2 are mitogen activated protein kinases (MAPKs) that play a central role in
the regulation of cell proliferation, differentiation, and survival (27). ERK1/2 signaling is
activated upon ligand binding to membrane receptors and subsequent activation of the
small GTPase Ras, which phosphorylates and activates the MAP kinase kinase kinase
(MAPKKK) Raf (28). Activated Raf phosphorylates the MAP kinase kinases (MAPKKs)
MEK1 and MEK2 (MEK1/2), which phosphorylate and activate ERK1/2 (28). Activated
ERK1/2 phosphorylates a large number of cytosolic substrates to regulate diverse cellular
functions and can also be translocated to the nucleus where it activates transcription factors
regulating gene expression (27-29). Deregulation of Ras/MAPK signaling contributes to
approximately one-third of human cancers (30, 31)
Coordination of the Raf/MEK/ERK protein complex and subsequent ERK1/2
phosphorylation is regulated by the scaffold protein kinase suppressor of Ras 1 (KSR1)
(32-34). KSR1 coordinates formation of the Raf/MEK/ERK signaling complex, increasing
specificity of MEK phosphorylation by Ras and ERK1/2 phosphorylation by MEK (3537). Though a recent study presents contrasting evidence suggesting KSR1 allosterically
regulates the interaction between Raf/MEK/ERK, the stimulatory effect of KSR1 on
ERK1/2 remains well-substantiated (38). KSR1 is required for Ras-induced transformation
of mouse embryonic fibroblasts (MEFs) and increases proliferative potential of mammary
epithelial cells when expressed at optimal levels (34). KSR1-deficient mice exhibit reduced
Ras-dependent mammary tumor formation (39, 40). In the absence of KSR1, high
molecular weight complexes containing KSR1, ERK, and MEK are abolished, and KSR1
knockout mice exhibit reduced ERK signaling (40). Furthermore, reintroduction of KSR1
into KSR1-deficient mice rescues ERK signaling (34). However, KSR1 is not required for
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ERK signaling or normal embryonic development. KSR1-deficient mice develop normally,
despite attenuated ERK signaling and slightly reduced T-cell activation (35, 40). Because
KSR1 promotes Ras and ERK activation and yet is dispensable for normal development,
its potential as a therapeutic target for Ras-driven cancers is being widely investigated (41).
Given the role of NT downstream of Ras and ERK1/2 signaling, we reasoned that KSR1
may also regulate NT secretion.
In this study, we examine the role of KSR1 in NT secretion and ERK1/2 signaling
in the human endocrine cell lines BON and QGP-1. We demonstrate that inhibition of
KSR1 reduces, while its overexpression enhances NT secretion and ERK1/2 signaling. We
also show that Exo70, a component of the exocyst complex and direct substrate of ERK2,
positively regulates NT secretion. These findings describe a role for KSR1 as a positive
regulator of NT secretion through activation of the ERK1/2 signaling pathway and suggest
that the interaction between ERK2 and Exo70 contributes to NT secretion in human
endocrine cells.
3.3 Results
3.3.1 KSR1 inhibition reduces NT secretion
KSR1 is expressed in intestinal epithelial cells, where it is protective against
cytokine-induced injury (106, 107). NT is secreted from specialized enteroendocrine (N)
cells of the small intestine and is stimulated by ingestion of dietary fats (30, 31, 33, 108).
To determine whether KSR1 is expressed in human endocrine cells and characterize its
localization relative to NT, we used the BON cell line, which synthesizes and secretes NT
in a manner equivalent to that of N cells in the small bowel. BON cells were transfected
with CFP-tagged KSR1 plasmid DNA to enable detection of KSR1with fluorescent
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confocal microscopy at 488nm and subsequently labeled with fluorescent anti-NT antibody
(100). Consistent with previous evidence, we show that NT is localized to secretory
vesicles in human endocrine cells, while KSR1 exhibits diffuse cytosolic staining (Fig 3.1).
Interestingly, distribution of KSR1 and NT is largely mutually exclusive, where KSR1
expressing cells do not contain NT-containing secretory vesicles and cells retaining large
amounts of NT do not express high levels of KSR1. This observation suggests that KSR1
expression promotes release of NT vesicles from N cells.
We have previously demonstrated that ERK1/2 plays a stimulatory role in NT
secretion (43, 44). The function of KSR1 as a scaffold of the Raf/MEK/ERK complex has
been reported to enhance ERK1/2 signaling (109-111). To determine whether KSR1 is
involved in NT secretion, we transfected BON cells with small interfering RNA (siRNA)
against KSR1. Forty-eight h after transfection, cells were treated for 90 min with
docosahexaenoic acid (DHA), a long-chain unsaturated FA that we have previously shown
stimulates NT secretion, thereby mimicking the effects of fat-ingestion in the small bowel.
KSR1 knockdown was confirmed via qRT-PCR and NT secretion was measured using NTEIA. Consistently, inhibition of KSR1 attenuates DHA-stimulated NT secretion (Fig
3.2A).
To verify these results, we next established BON cell lines stably expressing KSR1targeting shRNA. shRNA-mediated knockdown of KSR1 reduces basal and DHAstimulated NT secretion from BON cells (Fig 3.2B). To further confirm these findings, we
established KSR1 knockdown using siRNA in another human endocrine cell line, QGP-1.
QGP-1 cells, derived from a pancreatic somatostatinoma, produce and secrete high levels
of NT in response to FA-stimulation, including DHA (43). Consistent with the effect of
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KSR1 on NT secretion in BON cells, inhibition of KSR1 in QGP-1 cells reduces basal and
DHA-stimulated NT-secretion (Fig 3.2C). Together, these data demonstrate that KSR1
regulates NT release from human endocrine cells.
3.3.2 KSR1 inhibition reduces ERK1/2 phosphorylation
The scaffolding function of KSR1 on the Raf/MEK/ERK complex has been
demonstrated to coordinate and enhance ERK1/2 activation (17, 18, 44, 112). KSR1deficient mice exhibit attenuated ERK1/2 signaling and a reduction in MEK- and ERKcontaining high molecular weight complexes (113). To determine whether the effect of
KSR1 on NT secretion is mediated by the ERK1/2 signaling pathway, BON and QGP-1
cells transfected with KSR1-targeting siRNA were treated with DHA to stimulate NT
secretion and lysed for western blotting. Consistently, inhibition of KSR1 decreased
ERK1/2 phosphorylation (p-ERK) (Fig 3.3). These findings are consistent with studies
demonstrating that KSR1 positively regulates ERK1/2 signaling and indicate that the effect
of KSR1 on NT secretion in human endocrine cells is mediated by its interaction with the
Raf/MEK/ERK signaling complex.
3.3.3 KSR1 overexpression stimulates NT secretion and ERK activity.
As a scaffold protein, KSR1 can produce both inhibitory and stimulatory effects on
ERK1/2 signaling when overexpressed (109). At optimal expression levels, KSR1
facilitates maximal coordination of Raf/MEK/ERK and enhances ERK1/2 signaling, while
at levels above or below this threshold, ERK1/2 signaling is inhibited. As such, the effects
of KSR1 overexpression are tissue specific and based on endogenous levels of KSR1
expression (109, 112, 113). To determine the effects of KSR1 overexpression on ERK1/2
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signaling in human endocrine cells, we transfected BON cells with KSR1-overexpressing
plasmids and performed western blot to assess ERK1/2 activation. Overexpression of
KSR1 enhances ERK1/2 phosphorylation, suggesting that endogenous KSR1 expression
in BON cells is below the threshold for coordinating maximal Raf/MEK/ERK signaling
(Fig 3.4A). To determine whether the effect of KSR1 overexpression on ERK1/2 signaling
corresponds to an increase in FA-stimulated NT secretion, we overexpressed KSR1 in
BON and QGP-1 cells and performed NT-EIA. Consistent with the observed increase in
ERK1/2 signaling, DHA-stimulated NT secretion is enhanced by KSR1 overexpression
(Fig 3.4B-C). These data establish KSR1 as a positive regulator of FA-mediated NT
secretion in endocrine cells through activation of the Raf/MEK/ERK signaling pathway.
3.3.4 Exo70 positively regulates NT secretion
Upon extracellular stimulation of NT release, NT-containing vesicles are
transported to the plasma membrane for exocytosis and extracellular release (37, 38).
Tethering of secretory vesicles to the plasma membrane prior to secretion is mediated by
the exocyst, an octameric protein complex comprised of Sec3, Sec5, Sec6, Sec8, Sec10,
Sec15, Exo70, and Exo84 (114, 115). Exo70 is a direct substrate of ERK2, which
phosphorylates Exo70 at Ser250 and thereby modulates the processes mediating vesicle
exocytosis (116). Whether Exo70 regulates exocytosis of NT secretory vesicles is
unknown. To determine whether Exo70 is involved in ERK-mediated NT secretion, we
generated BON cell lines stably expressing ERK2 shRNA. Consistent with previous
reports, ERK2 inhibition reduces Exo70 expression in BON cells (Fig 3.5A) (116). NT
secretion is also significantly attenuated by ERK2 knockdown (Fig 3.5B). To verify these
results, we pre-treated BON cells with the MEK inhibitor PD 98059 to inhibit
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phosphorylation of ERK1/2. MEK inhibition abolished ERK1/2 phosphorylation in basal
and DHA-stimulated BON cells (Fig 3.5C) and inhibited DHA-stimulated NT secretion
(Fig 3.5D).
To further confirm the role of Exo70 in NT secretion, we generated BON cell lines
stably expressing Exo70 shRNA and measured constitutive and FA-stimulated NT
secretion. Inhibition of Exo70 potently inhibits NT secretion from both untreated and
DHA-stimulated BON cells (Fig 3.6A). Conversely, overexpression of Exo70 enhances
both basal and DHA-stimulated NT secretion (Fig 3.6B). Moreover, western blot analysis
demonstrates that ERK1/2 phosphorylation is attenuated by Exo70 inhibition (Fig 3.6C).
Collectively, these data implicate Exo70 as a positive regulator of NT secretion and suggest
that the interaction between ERK1/2 and the exocyst complex may mediate exocytosis of
NT vesicles from enteroendocrine cells.
3.4 Discussion
FAs and NT play stimulatory and intersecting roles in the development of obesity
and cancer. Our group recently demonstrated that stimulation of NT secretion by the
unsaturated FA, DHA, is mediated by ERK1/2 signaling (43, 44). Here, we examine the
role of KSR1 on DHA-stimulated NT secretion. We show that KSR1 promotes DHAstimulated NT secretion through the ERK1/2 signaling pathway. We also show that Exo70
inhibition reduces, while its overexpression enhances NT secretion and ERK1/2
phosphorylation. Collectively, the data presented in our current study implicate KSR1 and
Exo70 as positive regulators of NT secretion that are integrated through the ERK1/2
signaling pathway.
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KSR1 serves as a scaffold of the Raf/MEK/ERK complex, coordinating the spatial
interactions between RAF, MEK, and ERK and enhancing specificity of their sequential
phosphorylation (111, 113). These interactions make KSR1 a potent regulator of ERK1/2
signaling (109-112). We show that KSR1 inhibition reduces DHA-stimulated NT secretion
and correspondingly inhibits ERK1/2 phosphorylation in human endocrine cells. In
contrast, overexpression of KSR1 enhances NT secretion, and ERK1/2 phosphorylation.
Given the role of KSR1 as a positive regulator of ERK1/2 signaling and our previous
studies showing that ERK1/2 enhances NT mRNA expression and peptide secretion, these
data suggest that KSR1 positively regulates NT secretion through the Raf/MEK/ERK
signaling cascade (43, 44). KSR1 has been similarly shown to regulate secretion of insulin
and inflammatory cytokines, though whether its role in secretion is predominantly positive
or negative is unclear (117, 118). KSR1-deficient mice have higher levels of basal insulin
release relative to wild-type mice, suggesting that KSR1 negatively regulates insulin
secretion (118). In T-lymphocytes and splenocytes from KSR1-deficient mice, interferon
gamma (IFN-γ) secretion is enhanced relative to wild-type cells, suggesting a negative role
for KSR1 in IFN-γ secretion (117). However, KSR1-deficient T cells exhibit reduced
interleukin 17A (IL17A) secretion, suggesting that KSR1 enhances IL17A secretion (117).
These contrasting findings may be attributable to the role of KSR1 as a scaffold
protein, which can play negative or positive roles in signal transduction depending on their
expression level (109, 119-121). Scaffold proteins facilitate maximal signaling when
expressed in approximate stoichiometry with their ligands (119). Scaffold inhibition
reduces signaling due to depletion of the scaffold, yet scaffold overexpression can also
inhibit signaling due to sequestration of the ligands, unless the ligands themselves are also

40

overexpressed (119). However, in cells endogenously expressing high levels of scaffold,
inhibition may bring the scaffold and its ligands to near equivalent amounts, thereby
increasing signaling (119). The conflicting evidence regarding the role of KSR1 in
secretory processes may be attributable to variation in endogenous expression levels of
KSR1 and its ligands between cell types.
In mouse embryonic fibroblasts (MEFs), expression of KSR1 at 14 times
endogenous levels produces maximal ERK1/2 signaling, while levels exceeding this
reduce ERK1/2 signaling to levels comparable to that of KSR1-deficient cells (112). In
contrast, ectopic expression of KSR1 in 293T cells inhibits insulin- and phorbol myristate
acetate (PMA)-stimulated ERK1/2 signaling (122). We show that overexpression of KSR1
enhances ERK1/2 phosphorylation and DHA-stimulated NT secretion in neuroendocrine
cells. These data suggest that, like MEFs, endogenous KSR1 expression in neuroendocrine
cells is below that of the threshold for maximal ERK activation. Alternatively, components
of the Raf/MEK/ERK complex may also be overexpressed in response to the downstream
effects of ectopic KSR1 expression, thereby restoring stoichiometry of the complex. NT
has been shown to activate ERK signaling through Ras activation (54). Stimulation of NT
by overexpression of KSR1 may therefore feedback positively on ERK1/2, optimizing
signaling of the Raf/MEK/ERK complex.
As a secreted peptide, NT is subject to regulation by exocytotic processes, including
vesicle trafficking, docking, and fusion with the plasma membrane (37, 38). Exo70, a
component of the exocyst complex that regulates exocytosis, is localized to lipid rafts on
the plasma membrane and facilitates docking of secretory vesicles to the membrane prior
to secretion (114, 115). Exo70 is a direct substrate of ERK2, which phosphorylates Exo70
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at Ser250 upon EGF stimulation (68). We have recently demonstrated that DHA-stimulated
NT secretion is mediated by an ERK1/2-dependent mechanism in neuroendocrine cells and
C57/BL6 mice (43). In our current study, we show that ERK2 knockdown reduces
expression of total Exo70, though no antibodies are currently available for detection of
phosphorylated Exo70. Ablation of ERK1/2 phosphorylation with the MEK inhibitor PD
98059 also abrogated Exo70 expression and NT-secretion. These findings support other
studies demonstrating that ERK2 positively regulates Exo70 and promotes its interaction
with other components of the exocyst complex (116). Activation of Exo70 by ERK1/2
signaling also mediates vesicular trafficking and matrix metalloproteinase (MMP)
secretion in MDA-MB-231 human breast cancer cells (116). Our results corroborate these
findings and provide further evidence to support the role of ERK1/2 signaling as a regulator
of Exo70-mediated secretory processes.
We also find that Exo70 knockdown potently inhibits both basal and DHAstimulated NT secretion. In contrast, Exo70 overexpression enhances basal and DHAstimulated NT secretion, suggesting a positive role for Exo70 in regulating NT secretion.
Consistent with our findings, Lopez et. al (123) showed that Exo70 regulates insulin
secretion. Insulin granules associate with Exo70 at the plasma membrane of β-cells,
suggesting that Exo70 facilitates docking of insulin granules with the membrane (123).
Exo70 is also required for proper docking of Glut4-containing vesicles with the plasma
membrane during insulin-stimulated Glut4 secretion (124). Additionally, we show that
inhibition of Exo70 attenuates ERK1/2 phosphorylation, suggesting a role for Exo70 in
feedback activation of ERK1/2 signaling. Notably, Exo70 mRNA and protein is
overexpressed in colon cancer, in which both ERK1/2 and NT are also heavily implicated
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(125). The exocyst complex has also been implicated in the epithelial-mesenchymal
transition (EMT) in mammary epithelial cells (125, 126). Studies aimed at further
delineating the interaction between Exo70 and ERK1/2 may shed light on their role in
processes regulating both secretion and tumorigenesis.
In summary, the present studies demonstrate for the first time that KSR1 positively
regulates FA-stimulated NT secretion and that this effect is mediated by the stimulatory
effect of KSR1 on ERK1/2 signaling. Moreover, we reveal a novel role for Exo70 in the
regulation of NT secretion (Fig 3.6D). We also describe a role for ERK1/2 in NT secretion
independent of its previously described role on NT mRNA and protein expression by
demonstrating its stimulatory effect on the secretory processes mediating NT release.
Collectively, these data indicate that KSR1 modulation may have therapeutic potential for
diseases driven by NT gene expression and peptide secretion, such as obesity-associated
metabolic disorders and Ras-driven cancers.

43

Fig 3.1. KSR1 expression stimulates NT release from BON cells. BON cells were
transfected with pECFP-N-KSR1 (green) and labeled with immunofluorescent anti-NT
antibody (red) and observed via confocal microscopy with 40x objective. White arrows
indicate KSR1-positive cells, yellow arrows indicate NT labeling. Scale bar indicates
20µm.
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Fig 3.2. KSR1 inhibition attenuates FA-stimulated NT secretion (A) BON cells were
transfected with KSR1-targeting siRNA or KSR1-targeting shRNA (B) and treated with or
without DHA for 90 min. Total RNA was isolated and qRT-PCR performed targeting
KSR1 with GAPDH as the internal control (left) (†p<0.05 vs. untreated NTC; *p<0.05 vs.
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NTC plus DHA). Media were collected and NT-EIA performed (right) (†p<0.05 vs.
untreated NTC; *p<0.05 vs. NTC plus DHA; ‡p<0.05 vs. untreated KSR1-siRNA/shRNA
groups. (C) QGP-1 cells were transfected with KSR1-targeting siRNA and treated with or
without DHA for 90 min. Total RNA was isolated and qRT-PCR performed targeting
KSR1 with GAPDH as internal control (left) (†p<0.05 vs. untreated NTC; *p<0.05 vs.
NTC plus DHA). Media were collected and NT-EIA performed (right) (†p<0.05 vs.
untreated NTC; *p<0.05 vs. NTC plus DHA; ‡p<0.05 vs. untreated KSR1-siRNA group).
All data represent mean +/- SD. Data are representative of three independent experiments.
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Fig 3.3. Knockdown of KSR1 attenuates ERK1/2 signaling. (A) BON and (B) QGP-1
cells were transfected with KSR1-targeting siRNA and treated with or without 100µM
DHA for 90 min. Cells were lysed and western blotting analysis performed. Band intensity
is indicated below the corresponding band and expressed as fold-change relative to NTC.
Each blot is representative of three independent experiments.
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Fig 3.4. Overexpression of KSR1 enhances NT secretion and ERK activation. (A)
BON cells were transfected with pEGFP-control and pECFP-N-KSR1 plasmid DNA and
QGP-1 cells were transfected with MSCV-IRES-GFP and MSCV-KSR1-IRES-GFP
plasmid DNA (B) and treated with or without 100µM DHA for 90 min. Cells were lysed
and western blotting analysis performed. Band intensity is indicated below the
corresponding band and expressed as fold-change relative to NTC. Each blot is
representative of two independent experiments. (C) BON cells were transfected with
pEGFP-control and pECFP-N-KSR1 plasmid DNA and QGP-1 cells were transfected with
MSCV-IRES-GFP and MSCV-KSR1-IRES-GFP plasmid DNA (D) and treated with or
without 100µM DHA for 90 min. Media were collected and NT-EIA performed. Panel (C):
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†p<0.05 vs. untreated pEGFP; *p<0.05 vs. pEGFP plus DHA; ‡p<0.05 vs. untreated CFPKSR1; Panel (D): †p<0.05 vs. untreated MSCV-GFP; *p<0.05 vs. MSCV-GFP plus DHA;
‡p<0.05 vs. untreated MSCV-GFP-KSR1. Data represent mean +/- SD and are
representative of three independent experiments.

49

A(a)

shRNA
DHA

-

C
(c)

ERK2

NTC

+

-

+

DHA

+

-

+

1

.94

.79

.43

1

3.8

0

0

1

.46

1.1

1.3

Exo70

Exo70

1

.85

.66

.56
p-ERK1
p-ERK2

p-ERK1
p-ERK2

1

1.3

0.45

0.48
ERK1
ERK2

ERK1
ERK2

1

.88

.67

.68
β-actin

β-actin

B(b)

(d)
D

#

2.5
2
1.5
1

†

0.5

*

0

DHA
shRNA

6
5

+
NTC

-

3
2

†

1

DHA

+

‡*

4

0

-

#

7

NT Secretion (Fold Change)

3

NT Secretion (Fold Change)

PD

DMSO

-

-

+

DMSO

ERK2

-

+
PD

Fig 3.5. ERK1/2 inhibition attenuates Exo70 expression. (A) BON cells stably
expressing NTC or ERK2 shRNAs were treated with or without 30µM DHA for 90 min.
Cells were lysed and western blotting analysis performed. Band intensity is indicated below
the corresponding band and expressed as fold-change relative to NTC. (B) Media were
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DHA; data represent mean +/- SD). (C) BON cells pre-treated with DMSO or PD 0325901
for 30 minutes were treated with or without 100µM DHA for 90 min. Cells were lysed and
western blotting analysis performed. Band intensity is indicated below the corresponding
band and expressed as fold-change relative to NTC. (D) Media were collected and NT-EIA
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performed (†p<0.05 vs. DMSO without DHA; *p<0.05 vs. DMSO plus DHA; ‡p<0.05 vs.
PD without DHA; data represent mean +/- SD). All data are representative of three
independent experiments.
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Fig 3.6. Exo70 positively regulates NT secretion. (a) BON cells stably expressing NTC
or Exo70 shRNAs were treated with or without 30µM DHA for 90 min. Media were
collected and NT-EIA performed (†p<0.05 vs. untreated NTC; *p<0.05 vs. NTC plus
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DHA; data represent mean +/- SD). (b) BON cells were transfected with pEGFP-control
or pEGFP-C3-Exo70 plasmid DNA and treated with or without 30µM DHA for 90 min.
Media were collected and NT-EIA performed (†p<0.05 vs. untreated pEGFP; *p<0.05 vs.
pEGFP plus DHA; ‡p<0.05 vs. untreated pEGFP-Exo70; data represent mean +/- SD). (c)
BON cells stably expressing NTC or Exo70 shRNAs were treated with or without 30µM
DHA for 90 min. Cells were lysed and western blotting analysis performed. Band intensity
is indicated below the corresponding band and expressed as fold-change relative to NTC.
All data are representative of three independent experiments. (d) Proposed model of
KSR1/ERK/Exo70 signaling in the control of NT secretion.
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CHAPTER 4:
NEUROTENSIN PROMOTES STEM CELL FUNCTION IN THE SMALL
INTESTINE AND COLORECTAL CANCER CELLS
4.1 Abstract
Actively cycling intestinal stem cells (ISCs), expressing the WNT target gene Lgr5,
are highly proliferative and metabolically active, and are sensitive to dietary alterations and
nutrient availability. Neurotensin (NT), a gut peptide localized predominantly to the small
bowel and released by fat ingestion, stimulates the growth of intestinal mucosa under basal
conditions and with nutrient deprivation, suggesting a possible role for NT on ISC function.
Here we demonstrate that NT regulates proliferation and stem cell function in the small
intestine and that these effects are highly dependent on nutrient state. Under nutrient-rich
conditions, NT stimulates ERK1/2 signaling and the expression of genes that promote cell
cycle progression, including cyclin D1, leading to maintenance of crypt cell proliferation.
Under conditions of nutrient depletion, NT stimulates WNT/b-catenin signaling and
promotes an ISC gene signature, leading to enhanced ISC function. Importantly, we show
that NT is required for the induction of WNT/b-catenin signaling and ISC-specific gene
expression during nutrient depletion. Functionally, loss of NT reduces crypt cell
proliferation and impairs ISC function and Lgr5 expression in the intestine during fasting.
Conversely, the expression of NT in the midgut enteroendocrine cells of Drosophila
prevents loss of ISCs during nutrient deprivation. Collectively, our findings establish an
evolutionarily-conserved role for NT in ISC maintenance during nutritional stress.
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4.2 Introduction
The intestinal mucosa is in a continuous state of proliferation with complete
epithelial cell turnover occurring every 4-5 days (2, 127). This rapid self-renewal process
is maintained by intestinal stem cells (ISCs) that reside at the base of intestinal crypts (4).
ISCs give rise to progenitor cells that rapidly proliferate within the crypt and terminally
differentiate as they progress up the crypt-villus axis. Progenitor cells differentiate into
either absorptive (enterocytes) or secretory (goblet, Paneth, enteroendocrine [EE]) cells
that carry out the primary functions of the intestinal epithelium, including nutrient
absorption, digestion, and protection from microbial infections (2, 4, 5). The process of
proliferation and differentiation within the small intestine is highly sensitive to nutrient
state. Nutrient deprivation causes atrophy of the intestinal mucosa, reduces crypt cell
proliferation, and enhances crypt and villus cell apoptosis (28). In contrast, ISC function is
enhanced by short-term fasting, and ISC numbers are increased by long-term calorie
restriction (26, 27). Proliferation and stem cell function in the small intestine are controlled
by signaling pathways that are tightly coupled to metabolic status, including mitogenactivated protein kinase (MAPK) and WNT/b-catenin signaling (4, 128-131).
WNT/b-catenin signaling is an evolutionarily-conserved pathway that plays a
critical role in intestinal homeostasis (12). WNT/b-catenin signaling is activated by
translocation of b-catenin to the nucleus, where it activates expression of WNT-target
genes that regulate cell proliferation, embryonic development, and tissue homeostasis (6,
11). Reduction of WNT/b-catenin signaling in the intestine impairs crypt cell proliferation
and ISC function, whereas hyperactivation of the WNT/b-catenin pathway contributes to
neoplasia (6, 8). WNT ligands secreted from subepithelial mesenchymal cells and Paneth
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cells maintain high levels of WNT/b-catenin signaling at the base of intestinal crypts to
support rapid proliferation and ISC self-renewal (7, 132-134). In the mammalian small
intestine, active ISCs positioned at the base of crypts are specifically labeled by expression
of the WNT target gene Lgr5 (3, 7). Likewise, the Drosophila midgut epithelium is
replenished by a population of ISCs regulated, in part, by expression of the Drosophila
WNT homolog, wingless (wg) (12, 135). The WNT/b-catenin pathway is sensitive to
nutrient state and metabolic status. Excess dietary fat intake activates WNT/ -catenin
signaling in intestinal crypts, leading to enhanced stemness and tumorigenicity of ISCs and
progenitor cells (25). Free-fatty acids (FFAs) increase β-catenin target gene expression in
intestinal organoids, and high glucose levels are required for WNT-stimulated nuclear
translocation of β-catenin in enteroendocrine (EE) cells and various tumor-derived cell
lines (25, 136).
Nutrient state is a also a critical regulator of intestinal hormone release. The peptide
hormone neurotensin (NT) is localized to EE cells predominantly in the distal small
intestine (33, 35, 137). NT, released primarily by ingestion of dietary fats, facilitates
intestinal mucosal proliferation, FFA absorption, lipid metabolism, and glucose
homeostasis (36, 46, 137-139). The well-characterized physiologic effects of NT are
primarily endocrine-mediated; however, NT is also known to act in a paracrine and
autocrine fashion in some cell types, such as certain cancers and intestinal cells (39, 140,
141). NT signaling in the small intestine is predominantly mediated by the G-protein
coupled NT receptor 1 (NTR1), which leads to the activation of growth stimulating
pathways including PI3K/AKT and MAPK signaling (30, 51, 60, 142-145). Exogenous NT
stimulates growth of the normal intestinal mucosa, contributes to adaptation following
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intestinal injury, and has an anti-apoptotic role in intestinal epithelial cells and hepatocytes
(40, 45, 72, 74, 76, 146). NT has been implicated in regulation of the WNT/b-catenin
pathway in glioblastoma and hepatocellular carcinoma and is a downstream target of the
WNT pathway in neuroendocrine tumor cells (55, 64, 147). In colorectal cancer (CRC)
cells, NT mediates phosphorylation and inhibition of GSK3b, a repressor of WNT/bcatenin signaling (60, 147). Whether the intestinotrophic effect of NT is mediated through
the regulation of ISCs is not known. Here we demonstrate that NT differentially regulates
proliferation and stem cell function in the small intestine based on nutrient status. Under
nutrient-rich conditions, NT promotes crypt cell proliferation via ERK1/2 signaling and
positive regulation of the cell cycle, whereas during nutritional stress, NT promotes
WNT/b-catenin signaling and contributes to ISC maintenance in mice and Drosophila.
Collectively, our findings demonstrate that NT contributes to the maintenance of intestinal
homeostasis through regulation of ERK1/2 and WNT/b-catenin signaling and identify an
evolutionarily conserved role for NT in the maintenance of ISCs during nutritional stress.
4.3 Results
4.3.1 NT-deficiency impairs intestinal crypt cell proliferation.
We first investigated the impact of NT on the intestinal epithelium using Lgr5EGFP, NT wild type (Nt+/+) and Lgr5-EGFP, NT knockout (Nt-/-) mice. NT activates the
MAPK family members ERK1 and ERK2 (ERK1/2) in multiple cancer cell lines, including
CRC (142, 143). The ERK1/2 pathway is a master regulator of the cell cycle, and
MAPK/ERK signaling mediates ISC and crypt cell proliferation in the small intestine (4,
15). To determine whether NT contributes to ERK1/2 signaling or stemness in the small
intestine, we cultured organoids from Nt+/+and Nt-/- mice to examine ERK1/2 activation
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and ISC number. NT deficiency did not alter the appearance of intestinal organoids (Fig.
S4.1A); however, the absence of NT reduced phosphorylated ERK1/2 (p-ERK1/2)
expression by approximately 50% (Fig. S4.1B), which corresponded to an approximate
50% decrease in expression of the ISC markers Lgr5 and Olfm4 compared to
Nt+/+organoids (Fig. S4.1C-D). Fluorescence-activated cell sorting (FACS) analysis
revealed that NT deficiency reduced the percentage of Lgr5-GFP+ ISCs in intestinal
organoids by approximately 50% relative to intestinal organoids from Nt+/+ mice (Fig.
S4.1E), indicating that NT plays a role in maintenance of ISC number. However, the
number of Lgr5-GFP+ ISCs in freshly isolated crypts was unaltered by the absence of NT
(Fig. S4.1F), suggesting that other factors in the ISC niche likely compensate for the loss
of NT in vivo.
The reduction of ERK1/2 signaling and ISC number in Nt-/- organoids prompted us
to ask whether NT contributes to these functions in vivo under non-homeostatic conditions.
Under conditions of nutritional stress, including acute fasting or long term calorie
restriction, crypt proliferation is impaired and ISC function is altered (5). As an
intestinotrophic hormone released in response to nutrient ingestion, we hypothesized that
NT may contribute to intestinal adaptation depending upon the nutrient state (i.e, fed or
fasted). To investigate the role of NT in the small intestine during nutritional stress, Nt+/+
and Nt-/- mice were fed standard chow ad libitum (AL) or fasted for 48 h. We confirmed
loss of NT by evaluating Nt mRNA from intestinal crypts (Fig. S4.2A). Both Nt+/+ and Nt/-

mice lost approximately 20% of their body weight compared with AL-fed mice; there

was no difference in body weight between fasted Nt+/+ and Nt-/- mice (Fig. S4.2B).
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NT has been shown to promote ERK1/2 signaling in various CRC cell lines in vitro, yet
whether NT regulates ERK1/2 signaling in the small intestine in vivo is not known. In
organoids from Nt-/- mice, pERK1/2 expression was downregulated relative to Nt+/+
organoids (Fig. S4.1B), indicating that NT promotes ERK1/2 signaling in intestinal cells
ex vivo . To determine whether NT regulates the ERK1/2 pathway in vivo, we measured pERK1/2 in crypts isolated from AL and fasted Nt+/+ and Nt-/- mice. Consistent with our
findings in Nt-/- organoids, absence of NT reduced p-ERK1/2 expression in the crypts by
approximately 50% relative to AL-fed controls, although p-ERK1/2 expression was not
altered in the crypts of fasted Nt-/- mice (Fig. 4.1A). In agreement with this data, expression
of the ERK1/2 target gene, cyclin D1, was reduced by approximately 50% in crypts from
Nt-/- mice relative to AL-fed controls (Fig. 4.1B). Cyclin D1 expression was reduced to a
similar extent by fasting alone but was not further reduced by the absence of NT. To
quantify gene expression changes associated with NT during nutrient stress, we performed
a bulk RNAseq analysis using crypts isolated from AL-fed and fasted Nt+/+ and Nt-/- mice.
Because ERK1/2 and cyclin D1 are critical regulators of cell cycle progression and
proliferation, we performed a gene set enrichment analysis (GSEA) to better delineate the
role of NT on pathways regulating the cell cycle and cell proliferation. GSEA revealed that
absence of NT reduced expression of genes related to cell cycle progression, mitosis, and
DNA synthesis compared to AL-fed and fasted Nt+/+ mice (Fig. 4.1C-D), thus providing
further evidence that NT positively regulates crypt cell proliferation.
To validate these results in vivo, we quantified expression of Marker of
Proliferation protein Ki67 (Ki67) (148) in the proximal and distal small intestine.
Consistent with previous studies (6, 48), fasting reduced the number of Ki67+ cells in the
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crypts by approximately 50% compared to AL-fed mice in both the proximal and distal
small intestine (Fig. 4.1E and Fig S4.2C-D). Moreover, absence of NT significantly
reduced the number of Ki67+ cells in the distal crypts under both AL-fed and fasted
conditions relative to Nt+/+ mice (Fig. 4.1E). However, NT deficiency did not impact the
frequency of Ki67+ cells in the proximal small intestine (Fig S4.2C-D), suggesting that the
effect of endogenous NT is greatest in the distal small intestine, where NT expression is
highest (149). The reduction in proliferating distal crypt cells in Nt-/- mice corresponded to
increased epithelial cell differentiation measured via Alcian blue staining of goblet cells.
Nt-/- approximately doubled the percentage of goblet cells in the distal crypts of AL-fed
and fasted mice compared to Nt+/+ mice (Fig 4.1F), whereas no significant changes were
observed in goblet cell frequency in the proximal small intestine (Fig. S4.2E-F). Together,
these data demonstrate that NT contributes to cell proliferation and differentiation in the
distal small intestine independent of nutrient status. These effects are likely mediated by
NT regulation of ERK1/2 signaling.
4.3.2 Fasting activates WNT/b-catenin signaling in a NT-dependent manner.
Crosstalk between NT/NTR1 and the WNT/b-catenin pathway has been
demonstrated in multiple cancer cell lines (55, 64, 147), yet whether NT regulates WNT/bcatenin signaling in the small intestine is unknown. To determine whether NT-mediated
effects on intestinal proliferation are associated with alterations in the WNT/b-catenin
pathway, we examined expression of the TCF/LEF transcription factor Tcf7, a main
effector of WNT/b-catenin signaling (150), in crypts from AL-fed and fasted Nt+/+ and Nt/-

mice. Strikingly, despite reducing crypt cell proliferation, fasting increased Tcf7 mRNA

expression by approximately 80% in Nt+/+ crypts relative to AL-fed controls (Fig. 4.2A).
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Although the absence of NT had no impact on Tcf7 mRNA in the crypts of AL-fed mice,
loss of NT completely abrogated the induction of Tcf7 mRNA during fasting. We observed
a similar expression of the WNT target gene c-myc, which was increased by approximately
80% in fasted Nt+/+ crypts but was not increased in the crypts of fasted Nt-/- mice (Fig.
4.2B). In agreement with WNT/b-catenin activation, fasting increased expression of activeb-catenin in the crypts from Nt+/+ mice by greater than 50% compared to crypts from ALfed Nt+/+ mice but did not increase active-b-catenin in the crypts from Nt-/- mice (Fig.
4.2C), suggesting that NT positively regulates WNT/b-catenin signaling during periods of
fasting.
To elucidate the mechanism by which NT activates WNT/b-catenin during fasting,
we next examined pathways downstream of NT signaling that may converge on the
WNT/b-catenin pathway. In CRCs, NT signaling promotes phosphorylation of GSK3b, a
negative regulator of WNT/b-catenin signaling (60). GSK3b phosphorylates b-catenin on
Ser33, Ser37, and Thr41, leading to ubiquitination and proteasomal degradation of bcatenin (13). Phosphorylation of GSK3b on Ser9 by AKT inhibits GSK3b activity, thereby
stabilizing b-catenin and enabling its nuclear translocation and activation of WNT
signaling (Fig. 4.2D) (14, 61, 62). To determine whether NT promotes WNT/b-catenin
signaling through regulation of GSK3b, we examined phosphorylation of GSK3b on Ser9
in crypts isolated from AL-fed and fasted Nt+/+ and Nt-/- mice. The absence of NT reduced
p-GSK3b expression relative to crypts harvested from Nt+/+ mice under both AL-fed and
fasted conditions (Fig. 4.2E). Though fasting alone did not alter the ratio of phosphor- and
total GSK3b, total GSK3b expression was significantly reduced by fasting (Fig. S4.2GH), suggesting GSK3b depletion as a potential mechanism for WNT/b-catenin activation
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during fasting. Consistent with p-GSK3b expression, Nt-/- reduced p-AKT expression by
approximately 50% in the crypts from AL-fed mice (Fig. 4.2E). Fasting alone reduced pAKT to a similar extent; however, no additional decrease of p-AKT was observed in the
crypts of fasted Nt-/- mice. These data demonstrate that NT contributes to the induction of
WNT/b-catenin signaling in the small intestine during fasting. Moreover, our findings
suggest that this induction may occur through NT regulation of the AKT/GSK3b pathway.
4.3.3 Exogenous NT activates WNT/b-catenin signaling in the small intestine.
We next determined whether exogenous NT activates WNT/b-catenin and
AKT/GSK3b signaling in the small intestine. qRT-PCR analysis revealed that intestinal
organoids do not express NTR1 (Fig. S2I), therefore we utilized an ex vivo full-thickness
intestine model for exogenous NT treatment. Full-thickness small intestine was isolated
from Nt+/+ mice and treated with NT (100nM or 1µM) in PBS for 15 or 30 min at 37°C.
Western blot analysis demonstrated increased AKT phosphorylation after a 15 min
incubation with either 100nM or 1µM NT (Fig 4.3A). After 30 min exposure, p-AKT
expression remained elevated relative to controls but was decreased relative to the 15 min
timepoint, indicating that short-term treatment with NT potently activates AKT signaling
in the small intestine. Consistent with AKT activation, we found that 15 min exposure to
100nM NT increased p-GSK3b and p-LRP6, a marker of WNT/b-catenin activation, by
approximately 10- and 2.5-fold, respectively (Fig 4.3A, 4.3C). In agreement with our
initial findings that NT depletion reduces ERK1/2 signaling in crypts, exogenous NT
increased phosphorylation of ERK1/2 by approximately 6-fold (Fig 4.3A, 4.3C).
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To further confirm that activation of these pathways was mediated by NT/NTR1
signaling, we treated full-thickness small intestine with 100nM NT for 15 min with or
without 20 min pre-treatment with the NTR1 inhibitor SR48692 (151). NT consistently
increased phosphorylation of AKT, GSK3b, LRP6, and ERK1/2, whereas pre-treatment
with SR48692 prevented NT-mediated phosphorylation of these proteins (Fig 4.3B, 4.3C).
Collectively, these data demonstrate that NT/NTR1 signaling activates WNT/b-catenin,
AKT/GSK3b, and ERK1/2 signaling in the small intestine.
4.3.4 NT promotes an ISC gene expression program during fasting.
WNT/b-catenin signaling is critical for the proliferation and maintenance of ISCs,
which are characterized by their high expression of WNT target genes, including Lgr5,
Ascl2, Sox9, Msi-1, and EphB3 (3, 4, 152-154). Consistent with activation of WNT/bcatenin signaling in the crypts of fasted Nt+/+ mice, RNAseq analysis showed that fasting
increased expression of ISC-specific genes in the crypts of Nt+/+ mice relative to AL-fed
controls, and that the absence of NT blunted the increase of these ISC markers during
fasting (Fig 4.4A). qRT-PCR was used to validate expression of Lgr5 and Ascl2, which are
highly restricted to active ISCs (4), and confirmed that fasting induced expression of these
ISC markers in Nt+/+ mice but not in Nt-/- mice (Fig 4.4B), indicating that NT is required
for the induction of an ISC gene signature during fasting (154). We next analyzed the
frequency of Lgr5+ cells in the crypts using FACS. In contrast to the pattern of Lgr5 mRNA
during fasting, neither fasting nor absence of NT altered the total number of Lgr5-GFP+
ISCs (Fig S4.2J). To more precisely delineate the localization of Lgr5 mRNA expression
in vivo, we performed single-molecule in situ hybridization in the distal small intestine,
where we observed that the effects of NT are most pronounced. In agreement with RNAseq
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and qRT-PCR analyses, fasting increased Lgr5 mRNA copies per crypt cell by 2-fold
relative to AL-fed controls, but did not significantly increase Lgr5 expression in the crypts
of Nt-/- mice (Fig 4.4C-D). Thus, rather than increasing the number of Lgr5+ ISCs, fasting
increased the expression of Lgr5 in the established population of ISCs and progenitor cells
in an NT-dependent manner.
4.3.5 NT increases ISC function during nutrient deprivation.
Fasting has been previously shown to augment ISC function without altering ISC
frequency (27, 29). To determine whether the NT-dependent increase in Lgr5 mRNA
expression during fasting is associated with changes in ISC function, crypts were isolated
from AL-fed and fasted Nt+/+ and Nt-/- mice for ex vivo colony formation assays. Consistent
with others (27), we found a greater than two-fold increase in organoid forming efficiency
in fasted Nt+/+ crypts relative to the crypts from AL-fed Nt+/+ mice (Fig 4.4E). However,
organoid formation was significantly reduced in the crypts from fasted Nt-/- mice compared
to Nt+/+ mice. Furthermore, analysis of EdU incorporation, an indicator of cell proliferation
(155), in crypt-derived organoids demonstrated a significant reduction in EdU uptake in
fasted Nt-/- mice relative to fasted Nt+/+ mice (Fig 4.4F-G). We next examined whether NT
augments fatty acid oxidation (FAO), which promotes ISC function during fasting via
activation of PPARd signaling and enhanced function of Cpt1a, the rate-limiting enzyme
in FAO (27). Interestingly, FAO and PPARd gene sets were enriched in Nt-/- mice relative
to Nt+/+ mice under both AL-fed and fasted conditions (Fig. S4.2K), suggesting a role for
NT in negative regulation of these pathways. However, no significant changes in the
PPARd target genes Cpt1a or Hmgcs2 were observed between fasted Nt+/+ and fasted Nt-/mice (Fig S4.2L), suggesting that the effects of NT on ISC function are not mediated by
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alterations in FAO. Instead, our findings indicate that NT increases ISC function during
fasting via upregulation of WNT-target genes (i.e. Lgr5) in ISCs and progenitor cells.
Regulation of the intestinal epithelium is highly conserved, such that similar
signaling pathways and cellular processes regulate intestinal homeostasis in the
mammalian and Drosophila intestine (135, 156). The Drosophila midgut is composed of
ISCs that differentiate into the same major lineages as those in the mammalian small
intestine, and ISC proliferation is regulated by expression of the Drosophila WNT homolog
wg (12, 135). Therefore, the Drosophila ISC reporter line esg-Gal4-GFP, in which GFP is
fused to the Drosophila ISC marker esgargot, is a powerful model for studying ISC
function (157). We previously identified CG9918 (Pyrokinin 1 receptor, PK1-R) as the
endogenous NTR-like receptor in Drosophila (46). NT expression in the Drosophila
midgut mimics the effects of NT on intestinal lipid absorption and AMPK activation in the
mammalian small intestine, suggesting that the effects of NT on the intestinal epithelium
are highly conserved (46). To further delineate the role of NT on ISC function, we
expressed human full-length NT cDNA in midgut EE cells using the EE cell-specific
tachykinin (TK) promoter and examined ISCs labeled by esg-Gal4-GFP (esg-GFP) (Fig
4.4H) (92, 158). esg-GFP+ TK-NT and esg-Gal4-GFP control flies were maintained for 5
d on a standard diet (SD) or a nutrient-reduced low-energy diet (LED) (93, 94). Consistent
with our previous findings, NT overexpression increased the accumulation of lipid droplets
in Drosophila midgut measured by Nile Red staining (Fig 4.4H, center panels) (46). In
flies fed SD, NT expression caused a slight but significant increase in esg-GFP+ ISCs
relative to control flies (Fig 4.4I). In flies fed LED, the frequency of esg-GFP+ ISCs was
reduced by over 50% compared to flies fed SD. However, expression of NT in flies fed
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LED restored esg-GFP+ ISCs numbers to that of control flies fed SD (Fig 4.4I). These data
indicate that NT promotes ISC frequency in Drosophila midgut and attenuates ISC
depletion during nutrient-deprivation. Collectively, our findings demonstrate that NT
contributes to the maintenance of ISCs in both mice and Drosophila during nutrientdepletion, thus indicating an evolutionarily-conserved function of NT on ISCs.

4.3.6 NT does not contribute to HFD-induced proliferation or ISC function
Work from our lab previously demonstrated that NT contributes to HFD-induced
obesity by increasing intestinal lipid absorption (46). Beyaz et al. demonstrated an
important role for HFD and FFAs in stimulating ISC function and stemness of progenitor
cells (25). The importance of nutrient state in regulation of ISCs by NT led us to ask
whether NT-mediated intestinal lipid absorption potentiates HFD-induced ISC function.
NT+/+ and NT-/- were fed HFD or low-fat diet (LFD) control chow and crypts isolated for
qRT-PCR analysis of the ISC markers Lgr5 and Olfm4. Consistent with Beyaz et al.,
expression of Olfm4 mRNA was significantly increased in mice fed HFD relative to mice
fed LFD but was not altered by NT-/- under either dietary condition (Fig 4.5A) (25). Though
we didn’t observe significant differences in Lgr5 mRNA expression across groups, we
observed a trend similar to that of Olf4m4 mRNA, with increased expression in mice fed
HFD relative to mice fed LFD. In colony formation assays, NT-/- did not alter organoid
forming efficiency of crypts fed LFD or HFD (Fig 4.5B), indicating that NT does not
contribute to HFD-induced ISC function.
Crypt cell proliferation is also enhanced in mice fed HFD relative to mice fed a
control diet (25). Having established NT as an important regulator of crypt cell
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proliferation in mice fed AL, we tested the effect of NT-/- on HFD-induced crypt cell
proliferation. Consistent with Beyaz et al., HFD significantly increased the number of
Ki67+ cells per crypt in the proximal and distal small intestine (Fig 4.6A-D) (25).
However, NT-/- did not reduce crypt cell proliferation under either dietary condition.
Collectively, these data indicate that the effects of NT on intestinal lipid absorption do not
contribute to HFD-induced ISC function or crypt cell proliferation. Taken together with
the results of our fasting study, these data suggest that NT serves a protective role on ISCs
that is critical to maintenance of ISC numbers and function during conditions of nutrient
stress. Under nutrient-rich conditions, which serve to enhance ISC function, protection of
ISCs is unnecessary and NT function on ISCs is dispensable.

4.3.7 NT promotes WNT/β-catenin signaling and CSC function in CRC cells
The role of NT on WNT/β-catenin signaling and ISC function prompted to ask
whether NT regulates stem cell function in CRC cells. Numerous studies have
demonstrated the role of NT/NTR1 signaling in promoting cancer cell growth,
proliferation, invasion, and tumor progression (47, 48). NTR1 is highly overexpressed in
CRCs and intestinal tumors relative to normal intestinal tissues, and high levels of NTR1
expression are associated with poor prognosis in CRC (50). Like crypt epithelial cells and
ISCs, proliferation and stemness of cancer cells are regulated, in part, by the ERK1/2 and
WNT/β-catenin pathways, and within heterogenous CRC cell populations, high WNTactivity identifies the CSC population (88, 159). Though NT has been implicated in
crosstalk with the WNT/β-catenin pathway in other cancers (55), whether NT promotes
WNT/β-catenin signaling or stem cell function in CRC is unknown.
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To examine the role of NT on WNT/β-catenin signaling in CRC cells, we used the
human colorectal adenocarcinoma cell line HT29, the human colon carcinoma cell line
HCT116, and the patient-derived CRC cell line PT130. Cells were treated with 100nM NT
for 15 min and WNT/β-catenin activation analyzed via western blot. Consistent with our
findings demonstrating that NT promotes WNT/β-catenin signaling in the normal small
intestine, NT treatment increased expression of active-β-catenin and p-LRP6 in all CRC
cell lines, indicating activation of the WNT/β-catenin pathway (Fig 4.7A). To validate
these results, we utilized an ex-vivo tumor organoid model derived from mouse models of
CRC. Mutations in APC are a leading cause of CRC in humans, which is exacerbated by
accumulation of additional mutations in oncogenic proteins such as K-ras and p-53 (160).
To mimic the effects of CRC in a mouse model, we utilized APCmin and APCmin;K-rasmt
mice (161, 162).
Tumor organoids were cultured from the small intestinal tumors of APCmin;Nt+/+
mice and treated with 100nM NT for 48 h. Treatment with NT increased expression pLRP6 and the WNT/β-catenin target c-Myc (Fig 4.7B). We further confirmed these
findings by examining expression of WNT target genes in APCmin;Nt+/+ after 48 h
treatment with NT. Consistent with activation of WNT/β-catenin signaling, NT treatment
increased expression of the WNT target genes Lgr5, Axin2, and c-Myc by approximately
two-fold relative to untreated tumor organoids (Fig 4.7C). Moreover, we observed similar
levels of upregulation of WNT target gene expression in tumor organoids derived from
APCmin;K-rasmt;Nt+/+ mice. To confirm that this was mediated by NT/NTR1 signaling, we
treated APCmin;K-rasmt;Nt+/+ tumor organoids with NT in the presence or absence of the
NTR1 inhibitor SR48692 (5 µM) (Fig 4.7D). Treatment with the NTR1 inhibitor alone or
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in combination with NT reduced expression of Lgr5, Axin2, and c-Myc mRNA relative to
controls. Collectively, these data demonstrate that NT promotes WNT/β-catenin signaling
in CRC cells and small intestinal tumor organoids in an NTR1-dependent manner.
Constitutive activation of WNT/β-catenin in CRC cells contributes to aberrant cell
proliferation and promotes stemness of CSCs (66, 88). Stemness of CRC cells is measured
via colony-formation assays that examine the ability of single tumor cells to form tumor
organoid colonies, which requires an undifferentiated cancer stem cell phenotype (163).
To determine whether NT-mediated activation of WNT/β-catenin signaling in CRC cells
was associated with increased clonogenicity of CSCs, we performed colony formation
assays on APCmin;Nt+/+ tumor organoids and HCT116 tumorspheres treated with NT.
Consistent with upregulation of WNT target gene expression, NT treatment enhanced
colony formation of single APCmin;Nt+/+ tumor organoid cells by approximately two-fold
and caused dose-dependent increases in HCT116 tumorsphere colony formation (Fig 4.8AB). Together, these data indicate that NT/NTR1 signaling activates WNT/β-catenin
signaling and enhances stem cell function in CRC cells.

4.3.8 NT induces LRP6 phosphorylation via ERK1/2 in CRCs and tumor organoids.
We next sought to define the mechanism by which NT may regulate WNT/βcatenin signaling in CRC cells. We demonstrated that NT positively regulates ERK1/2
signaling in the normal small intestine, and NT has previously been shown to promote
ERK1/2 phosphorylation in various CRC cell lines. In certain contexts, ERK1/2
phosphorylates LRP6 on Ser1490, leading to activation of WNT/β-catenin signaling (65).
We confirmed the role of NT on ERK1/2 signaling in our CRC models by treating HT29,
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HCT116, PT130 and APCmin;Nt+/+ tumor organoids with NT. ERK1/2 phosphorylation was
upregulated by treatment with 100nM NT in HT29, HCT116 and APCmin;Nt+/+ tumor
organoids (Fig 4.9A). NT treatment also increased p-ERK1/2 expression in PT130 cells,
but to a lesser extent than the other CRC cell lines even at the highest dose, which may
reflect lower levels of NTR1 expression (Fig 4.9B). We also observed increased mTORC1
activation in HT29, HCT116, and APCmin;Nt+/+ tumor organoids following NT treatment,
suggesting that the stimulatory effect of NT on CRC cell growth may be mediated in part
by the protein synthesis processes regulated by the mTOR signaling pathway (Fig 4.9C-F)
(164).
We next asked whether NT promotes phosphorylation of LRP6 via activation of
ERK1/2. HT29 and HCT116 cell were treated with 100nM NT for 15 min with or without
20 min pre-treatment with the MEK inhibitor PD0325901 (10 nM) to block NT-mediated
phosphorylation of ERK1/2. Treatment with NT produced consistent upregulation of pERK1/2 and p-LRP6 expression in both cell lines, whereas MEK inhibition blocked NTmediated phosphorylation of ERK1/2 and LRP6 (Fig 4.10). Notably, MEK inhibition
completely ablated p-LRP6 expression in HT29 cells even in the absence of NT, suggesting
that ERK1/2 signaling may be a critical mediator of WNT-activation in HT29 cells.
Collectively, these data demonstrate that NT mediates phosphorylation of LRP6 on
Ser1490 in CRCs via activation of ERK1/2 signaling. As phosphorylation of LRP6 on
Ser1490 is sufficient for WNT/β-catenin activation, and we observe enhanced active βcatenin and WNT-target gene expression following NT treatment, these findings suggest
that NT promotes WNT/β-catenin signaling via ERK1/2 mediated phosphorylation of
LRP6.
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4.3.9 Loss of NT reduces WNT/β-catenin signaling and CSC function in intestinal tumor
organoids.
Our findings in HCT116, HT29, and PT130 cells and APCmin NT+/+ tumor organoids
indicate that exogenous NT activates WNT/β-catenin signaling and enhances CSC
function. To determine the impact of NT-deficiency on CSC function, we utilized APCmin
NT+/+ and APCmin NT-/- mouse models. Tumor organoids cultured from single intestinal
tumor cells from APCmin NT+/+ mice were significantly larger than those cultured from
APCmin NT-/- mice, indicating reduced proliferation as a result of NT-deficiency (Fig
4.11A). We performed colony formation assays to examine the effect of NT on CSC
clonogenicity and found that colony forming efficiency and viability of tumor organoids
was reduced by approximately 60% and 80%, respectively, by NT-deficiency (Fig 4.11BC). Consistent with the positive role of NT on WNT/β-catenin activation, loss of NT
reduced expression of the WNT-target gene Axin2 by approximately 50%, suggesting that
absence of NT reduces WNT/β-catenin signaling in intestinal tumor cells (Fig 4.11D). In
addition, our preliminary analysis of survival of APCmin NT+/+ and APCmin NT-/- mice shows
that loss of NT significantly increases overall survival in APC mutant mice (Fig 4.12).
Collectively, these data suggest that NT contributes to stem cell function in CRC cells and
APC mutant mice via positive regulation of WNT/β-catenin signaling.
4.4 Discussion
Our study identifies a novel and evolutionarily-conserved role for NT, acting
through NTR1, in the nutrient-dependent regulation of ISC function. We find that NT
contributes to ISC maintenance in mice and Drosophila during nutritional stress and
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activates AKT/ GSK3b and WNT/b-catenin signaling in the small intestine. In addition,
we demonstrate that NT positively regulates WNT/b-catenin signaling and stem-like traits
in CRC cells and show that NT-deficiency reduces CSC function in CRC tumor organoids
and increases survival in APCmin mice. Previous studies show that NT contributes to stem
cell maintenance in hepatocellular carcinoma (85) and promotes stem-like traits in
glioblastoma cells (86), suggesting that NT regulates self-renewal and stem cell function
in multiple cellular contexts. Consistent with the role of NT on ISCs, glucagon-like peptide
2 (GLP-2) has been reported to exert similar protective effects on ISCs during intestinal
stress (79, 82). The GLP-2 analog teduglutide promotes ISC expansion after intestinal
resection, protects ISCs from radiation damage, and facilitates ISC repair during graftversus-host disease in mice and humans (165-167). Notably, GLP-2 prevents mucosal
atrophy caused by total parenteral nutrition (TPN) through activation of AKT/ GSK3b and
WNT/b-catenin signaling, suggesting that GLP-2 and NT exert their trophic effects
through a common mechanism (168). In a manner similar to that observed with GLP-2, NT
prevents mucosal hypoplasia caused by enteral feeding and facilitates mucosal repair
following chronic intestinal inflammation or small-bowel resection (72, 73, 75). In
addition, the enterotrophic effects of GLP-2 are enhanced by the presence of NT (83). The
analogous mechanism and functions of NT described here suggest that NT may provide
therapeutic benefits similar to those observed with GLP-2.
To confirm the positive role of NT on ISC function in mice, we performed a
complementary study using Drosophila, another powerful model of ISC physiology. We
have previously shown that constitutive NT expression in EE cells of the Drosophila
midgut increases lipid droplet accumulation and impairs AMPK signaling in a manner
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analogous to that observed in the mammalian small intestine (46), therefore establishing
Drosophila as another useful model for studying NT function. Corroborating the
observation that NT contributes to ISC maintenance in the mammalian small intestine, NT
expression increases ISC number in the midgut of Drosophila fed a standard diet and
prevents ISC loss during nutrient-depletion. Other intestinal hormones have demonstrated
similar nutrient-regulated effects on ISC proliferation in Drosophila (92). Deletion of EE
cells in Drosophila midgut prevents nutrient-stimulated expression of the Drosophila
insulin-like peptide 3 (Dilp3) and impairs ISC proliferation, whereas increasing EE cell
number promotes Dilp3 expression and ISC division, suggesting that EE cells are important
nutrient-sensing modulators of ISC homeostasis (92). Our findings lend further support to
the idea that EE cells, through gut hormone release, support ISC function in Drosophila,
and indicate that the role of NT on ISCs is highly conserved.
Our data suggest that NT plays a protective role on ISCs, which is consistent with
previous studies documenting the protective effects of exogenous NT in the small intestine.
NT administration reverses hypoplasia of the small intestinal mucosa in rats challenged
with a liquid elemental diet and promotes mucosal regeneration following small-bowel
resection (72, 73). Interestingly, several studies report a more pronounced effect for
exogenous NT on growth in the proximal small intestine relative to the distal small intestine
(41, 73). Our findings indicate that endogenous NT has a more prominent effect in the
distal crypts, which is likely due to the primarily distal localization of NT expression in the
small intestine. This highlights potential differences in the function of exogenous and
endogenous NT in regulation of intestinal function along the proximal-to-distal axis of the
small intestine and suggests that endogenous NT release from distal EE cells regulates the
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local ISC niche in a paracrine manner. Like NT, many other gut hormones are secreted
from EE cells that are localized to discrete regions of the intestine (169). Given the
important local effects of NT in the distal small intestine, it is interesting to speculate that
other gut hormones may exert similar paracrine functions that influence the local
microenvironment in which they are released. In addition to its trophic function, NT has
also demonstrated anti-apoptotic effects in gastrointestinal tissues (76). NT reduces
intestinal crypt cell apoptosis caused by obstructive jaundice and reduces caspase-3
expression in mouse models of colitis (77, 170). The collective pro-proliferative and antiapoptotic actions of NT suggest it plays a protective role on epithelial cells under various
stress conditions. We advance these findings to show that the protective function of NT in
the small intestine extends to ISCs challenged by nutrient-depletion.
Our data, utilizing mice deficient in NT, corroborate findings in a human model of
nutritional stress that show Lgr5 mRNA and WNT target gene expression are upregulated
in the crypts of human ileum after prolonged absence of enteral nutrients, despite a
reduction in total ISC numbers, suggesting that Lgr5 expression is enhanced in ISCs during
nutrient depletion in order to prime them for rapid proliferation upon the reintroduction of
nutrients (171). In light of our findings that NT contributes to the induction of Lgr5
expression in fasted crypts, NT may have therapeutic benefit to patients receiving
parenteral nutrition. Our findings also support that of other studies demonstrating enhanced
ISC function during fasting with no changes in ISC frequency (27, 29). Upregulation of
FAO via PPARd signaling and Cpt1a expression was shown to be critical for enhanced
ISC function after a 24h fast (27). In agreement with this, we find induction PPARd
signaling and FAO target genes, including Hmgcs2 and Cpt1a, in crypts from fasted mice
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relative to AL fed mice. However, we find that loss of NT impairs fasting-induced ISC
function without altering expression of Cpt1a, suggesting that the effect of NT on ISC
function during nutrient deprivation is independent of FAO or PPARd signaling. Instead,
we find that fasting promotes WNT/b-catenin signaling in intestinal crypts in a NTdependent manner. Mechanistically, NT increased Lgr5 mRNA expression in ISCs and
progenitor cells and conferred increased ISC function during fasting. As PPARd is a bcatenin-target gene, it is plausible that the increase in PPARd signaling during fasting
observed by us and others is a product of WNT/b-catenin activation (172).
NT-mediated activation of the WNT/b-catenin pathway corresponded to enhanced
phosphorylation of AKT and GSK3b. The role of NT on AKT/GSK3b signaling has been
demonstrated previously in CRCs, in which NT promotes phosphorylation of AKT and
GSK3b and enhances cell proliferation (60). Consistent with this, p-AKT and p-GSK3b
expression were enhanced by exogenous NT and attenuated by the absence of NT.
Phosphorylation of GSK3β by AKT is inhibitory, resulting in accumulation of active bcatenin and enhanced WNT/b-catenin signaling (14, 61, 62). Consistent with this model,
we found that NT upregulates expression of active b-catenin and WNT target genes during
fasting. Though we did not detect NT-dependent differences in AKT activity in fasted
crypts, our findings corroborate previous work demonstrating nearly undetectable levels of
p-AKT in crypts after a 48h fast (29). We speculate that the observed level of AKT activity
during fasting is the minimum required for crypt maintenance and is therefore not further
inhibited by loss of NT. Interestingly, loss of NT markedly reduces p-AKT and p-GSK3b
expression in the crypts of AL-fed without altering WNT pathway activation. We postulate
that under nutrient-rich conditions, in which the intestinal crypts are undergoing rapid
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proliferation, the effect of NT on these growth stimulating pathways serves mainly to
contribute to crypt cell proliferation. In light of our observation that fasting reduces total
GSK3β expression, the pool of GSK3β phosphorylated downstream of NT may become
more critical in regulation of WNT/b-catenin signaling during nutrient-deprivation.
This study also conclusively establishes NT as a positive regulator of ERK1/2
signaling in the small intestine. Under nutrient-rich conditions, exogenous NT activated,
whereas NT-deficiency attenuated ERK1/2 phosphorylation in the small intestine. ERK1/2
controls the G1 to S-phase and G2 to M-phase transitions of the cell cycle and regulates
cyclin D1 transcription during G1/S phase, and activation of ERK1/2 is required for Sphase entry and proliferation of intestinal epithelial cells (20, 21, 173-175). Consistent with
the role of ERK1/2 as a central regulator of cell cycle progression and cyclin D1, NTdeficiency significantly reduced cyclin D1 protein expression and impaired progenitor cell
proliferation in the distal crypts. Attenuation of crypt cell proliferation in Nt-/- mice was
associated with increased crypt cell differentiation, evident by the increase in cells stained
by Alcian blue, a marker of differentiated mucin-secreting goblet cells (176). Cyclin-CDK
complexes regulate the switch from active cell proliferation to terminal differentiation, and
cyclin D1 expression is inversely correlated with differentiation of goblet cells in multiple
mouse models (177-179). Thus, attenuation of cyclin D1 expression in Nt-/- mice may
impair crypt progenitor cell proliferation in favor of terminal differentiation. Together,
these data establish NT as a positive regulator of crypt cell proliferation, ERK1/2 signaling,
and cyclin D1 expression, and suggest that the trophic effects of NT in the small intestine
are mediated, in part, by positive regulation of the cell cycle.
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The role of NT on ISC function and activation of ERK1/2 and WNT/b-catenin
signaling led us to interrogate the role of NT on these pathways in CRC. Consistent with
previous work in glioblastoma cells suggesting that NT may promote WNT/β-catenin
signaling via ERK1/2 activation (55), we found that NT promoted LRP6 phosphorylation
and WNT activation in an ERK1/2 dependent manner. ERK1/2 kinase activity is known
phosphorylate LRP6 on Ser1490, leading to activation of the WNT pathway (65). In
support of this model, treatment with NT enhanced, whereas treatment with NT in
combination with MEK inhibition blocked phosphorylation of ERK1/2 and LRP6,
indicating that NT promotes LRP6 phosphorylation via ERK1/2 activation. Consistent with
increased WNT activation, NT treatment increased the expression of WNT target genes in
an NTR1-dependent manner and enhanced CSC function in HCT116 cells and APCmin
NT+/+ tumor organoids. In support of our findings, NT/NTR1 signaling has been shown to
promote WNT signaling in hepatocellular carcinoma and promote CSC-like traits in
hepatocellular carcinoma and glioblastoma cells (64, 85, 86). Our data extend these
findings to demonstrate a similar role for NT on stem cell function in CRC. Of important
clinical relevance, our preliminary findings indicate that NT-deficiency markedly reduces
CSC clonogenicity in APCmin tumor organoids, reduces WNT target gene expression, and
significantly increases survival in mouse models of CRC. Collectively, these findings
demonstrate that NT/NTR1 signaling activates WNT/β-catenin signaling via LRP6 and
ERK1/2 phosphorylation and establish NT as an important regulator of stem cell function
in CRC.
In conclusion, our study defines a novel function for NT in maintenance of stem
cell function in the normal small intestine and in CRC cells. We demonstrate that, through
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activation of ERK1/2 and WNT/b-catenin signaling in intestinal crypts, NT differentially
regulates progenitor cell proliferation and ISC function based on nutrient availability
(Figure 4 J). Moreover, we find that NT exerts these effects primarily in the distal small
intestine, and therefore increase our understanding of the paracrine effects of NT, which
we show include regulation of the local ISC niche in response to nutritional cues. We
further show that, in CRC cells, NT promotes WNT/b-catenin signaling via ERK/LRP6
signaling and enhances CSC function. These findings provide new insight into the local
effects of gut hormone function in the small intestine and suggest that gut hormones play
an important role in their local microenvironment in a paracrine manner. Collectively, we
reveal a novel role for NT on stem cell maintenance during nutritional stress and in CRC,
suggesting that NT serves as a critical link between nutrient-sensing pathways, intestinal
homeostasis, and tumorigenesis.
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Figure 4.1. Loss of NT impairs crypt cell proliferation and promotes differentiation.
(A) Representative western blot of phospho- and total-ERK1/2 in intestinal crypts isolated
from Nt+/+ and Nt-/- mice fed either ad libitum (AL) or fasted for 48 h. (Top) PhosphoERK1/2 expression was quantified relative to total ERK1/2 expression in n=5 mice per
group. (B) Representative western blot of cyclin D1 expression in intestinal crypts isolated
from Nt+/+ and Nt-/- mice fed either AL or fasted for 48 h. (Top) Cyclin D1 expression was
quantified relative to Actin in n=5 mice per group. (C) Heatplot of RNA-seq analysis
showing expression of genes from the Cell Cycle gene set in crypts isolated from Nt+/+ and
Nt-/- mice fed either AL or fasted for 48 h. n= 5 mice per group for Nt+/+ AL, Nt+/+ Fast,
and Nt-/- Fast groups, n=4 for Nt-/- AL group. (D) Enrichment plots generated by GSEA
for Mitosis and DNA Replication gene sets based on RNAseq data from crypts isolated
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**
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from Nt+/+ and Nt-/- mice fed either AL or fasted for 48 h. NES, normalized enrichment
score relative to Nt+/+ groups. q, False-discovery rate (FDR)-adjusted p-value. (E)
Representative Ki67 staining in distal intestinal crypts from Nt+/+ and Nt-/- mice fed either
AL or fasted for 48 h. (Right) Quantification of the average number of Ki67+ cells per
crypt over 50 crypts per section in n=6-7 mice per group. (F) Representative Alcian Blue
staining in distal intestinal crypts from Nt+/+ and Nt-/- mice fed either AL or fasted for 48
h. (Right) Quantification of the percentage of Alcian Blue+ cells per crypt over 50 crypts
per section in n= 5-6 mice per group. Data shown are means ± standard deviation (SD).
Significant differences are shown with asterisks. *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001; ns, not statistically significant. (Scale bars indicate 50µM).
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Figure 4.2. NT is required for induction of WNT/β-catenin signaling in intestinal
crypts during fasting.
(A) qRT-PCR analysis of Tcf7 mRNA expression in RNA from intestinal crypts isolated
from Nt+/+ and Nt-/- mice fed either ad libitum (AL) or fasted for 48 h. n= 5 mice per group.
(B) qRT-PCR analysis of c-Myc mRNA expression in RNA from intestinal crypts isolated
from Nt+/+ and Nt-/- mice fed either AL or fasted for 48 h. n=5 mice per group. (C)
Representative western blot of active- and total- β-catenin expression in intestinal crypts
isolated from Nt+/+ and Nt-/- mice fed either AL or fasted for 48 h. (Right) Active-β-catenin
expression was quantified relative to Actin expression in n=6-8 mice per group. (D)
Schematic of AKT/GSK3β mediated activation of the WNT/β-catenin pathway. AKT
phosphorylates and inhibits GSK3β, leading to β-catenin stabilization and nuclear
translocation. (E) Representative western blot of phospho- and total-AKT and phosphoand total-GSK3β expression in intestinal crypts isolated from Nt+/+ and Nt-/- mice fed either
AL or fasted for 48 h. (Right) Phospho-AKT and phospho-GSK3β expression were
quantified relative to total protein expression in n=5 mice per group. Data shown are
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Figure 4.3. Exogenous NT activates WNT/β-catenin signaling in the small intestine.
(A) Representative western blot analysis of proteins in the WNT/β-Catenin and
AKT/GSK3β signaling pathways in full-thickness small intestine treated with NT (100nM)
for 15 min, SR48692 (10µM) for 20 min, or pre-treated with SR48692 (10µM) for 20 min
and treated with NT (100nM) for 15 min. (B) Representative western blot of phospho and
total forms of AKT, GSK3β, LRP6, ERK1/2 in in full-thickness small intestine treated ex
vivo with 100nM or 1µM NT for 15 or 30 min. (C) Phosphorylated AKT, GSK3β, LRP6,
and ERK1/2 expression was quantified relative to total protein expression in n=3-4 mice
per group. Data shown are means ± standard deviation (SD). Significant differences are
shown with asterisks. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not
statistically significant.
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Figure 4.4. NT contributes to ISC maintenance during nutrient-stress.
(A) Heatplot of RNA-seq analysis showing expression of ISC-specific WNT-target genes
in crypts isolated from Nt+/+ and Nt-/- mice fed either ad libitum (AL) or fasted for 48 h. n=
5 mice per group for Nt+/+ AL, Nt+/+ Fast, and Nt-/- Fast groups, n=4 for Nt-/- AL group.
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(B) qRT-PCR analysis of Lgr5 and Ascl2 mRNA expression in RNA from intestinal crypts
isolated from Nt+/+ and Nt-/- mice fed either AL or fasted for 48 h. n= 5-8 mice per group.
(C) Representative images of Lgr5 in situ hybridization in distal crypts from Nt+/+ and Nt/-

mice fed either AL or fasted for 48 h. Scale bars indicate 50 µM. (Inset) Arrows indicate

Lgr5+ cells. (D) Quantification of Lgr5 mRNA copies per cell determined by in situ
hybridization. n=4 mice per group. (E) Organoid-forming efficiency of crypts from Nt+/+
and Nt-/- mice fed either AL or fasted for 48 h. n= 5-6 mice per group. (F) Representative
EdU staining and quantification of EdU positive cells (G) in primary organoids cultured
from Nt+/+ and Nt-/- mice fed either AL or fasted for 48 h. Scale bars indicate 100 µM. EdU
positive cells were quantified using Pearson’s coefficient of colocalization between EdU
and DAPI in 20-30 organoids from 3-4 mice per group.(H) Representative esg-GAL4GFP and Nile Red staining in the midgut of +/+ (control) and NT-expressing (TK-NT)
drosophila. (I) Quantification of esg-GAL4-GFP+ ISCs in the midgut of +/+ (control) and
NT-expressing (TK-NT) drosophila fed a standard diet (SD) or low-energy diet (LED).
Data represent the number of ISCs in 6-15 flies per group. (J) Summary of the nutrientstate dependent function of NT on crypt cell proliferation and ISC maintenance. Data
shown are means ± standard deviation (SD). Significant differences are shown with
asterisks. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not statistically
significant.
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(right) Olfm4 mRNA in crypts isolated from Nt+/+ and Nt-/- mice fed LFD or HFD. (B)
Colony forming efficiency of primary crypts isolated from Nt+/+ and Nt-/- mice fed LFD
or HFD. n= 4-5 mice per group. Significant differences are shown with asterisks. *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not statistically significant.
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Figure 4.8. NT promotes CSC function in CRCs and intestinal tumor organoids. (A)
Representative image of APCmin NT+/+ tumor organoids (top) and colony forming
efficiency (bottom) in APCmin NT+/+ tumor organoids treated with NT (100nM) for 72 h.
(B) Representative image of HCT116 tumorspheres (top) and colony forming efficiency
(bottom) in HCT116 tumorspheres treated with NT at the indicated doses for 72 h. Data
are representative of 2 independent experiments and are shown as means ± standard
deviation (SD). Significant differences are shown with asterisks. *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001; ns, not statistically significant.
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tumor organoids. (A) ERK1/2 phosphorylation in HCT116, HT29, and APCmin NT+/+
tumor organoids treated with 100nM NT for the indicated times. (B) ERK1/2
phosphorylation in PT130 cells treated with NT at the indicated concentrations for 15 min.
(C) mTORC1 signaling activation in HCT116 cells treated with 100nM NT for the
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organoids treated with 100nM NT for 15 min. (F) S6 activation in PT130 cells treated with
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independent experiments.
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Figure 4.11. NT-deficiency reduces CSC function and WNT-target gene expression in
APCmin tumor organoids. (A) Representative images of tumor organoids cultured from
APCmin NT+/+ and APCmin NT-/- tumors. (B) Colony formation and (C) viability of tumor
organoids cultured from APCmin NT+/+ and APCmin NT-/- tumors. (D) mRNA expression of
the WNT-target gene Axin2 in APCmin NT+/+ and APCmin NT-/- tumor organoids. Data are
representative of 2 independent experiments and are shown as means ± standard deviation
(SD). Significant differences are shown with asterisks. *P < 0.05; **P < 0.01; ***P <
0.001; ****P < 0.0001; ns, not statistically significant.
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Figure 4.12. NT-deficiency significantly increases the lifespan of APCmin mice. KaplanMeier curve shows the survival distribution of two cohorts of mice: APCmin NT+/+ and APCmin

NT-/-. Numbers of mice in the two cohorts are: APCmin NT+/+ (n=4) and APCmin NT-/-.(n=5).
Statistical significance (determined by Log Rank test) is given for comparisons between

APCmin NT+/+ and APCmin NT-/- (p<0.05).
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Supplemental Figure 4.1.

(A) Representative images of organoids from Nt+/+ and Nt-/- crypts. (B) Western blot
analysis of phospho- and total-ERK1/2 in organoids from Nt+/+ and Nt-/- crypts. Organoids
from n=3 mice per group are shown. Densitometry analysis was performed on western
blots of organoids from n=5 mice per group. (C) Lgr5 and (D) Olfm4 mRNA expression in
organoids cultured from Nt+/+ and Nt-/-crypts. N=5 mice per group. (E) Lgr5-GFP+ ISC
frequency in organoids cultured from Nt+/+ and Nt-/- crypts. N=3 mice per group. (F) Lgr5GFP+ ISC frequency in freshly isolated crypts from Nt+/+ and Nt-/- mice fed ad libitum.
N=3-4 mice per group. Data shown are means ± standard deviation (SD). Significant
differences are shown with asterisks. *P < 0.05; **P < 0.01; ***P < 0.001; ****P <
0.0001; ns, not statistically significant. Scale bars indicate 100 µM.
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(A)Nt mRNA expression in crypts isolated from Nt+/+ and Nt-/- mice fed AL or fasted for
48 h. n=7-8 mice per group. (B) Body weight of Nt+/+ and Nt-/- mice fed AL or fasted for
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48h. n= 5-11 mice per group. (C) Representative Ki67 staining in proximal intestinal
crypts from Nt+/+ and Nt-/- mice fed either AL or fasted for 48 h. (D) Quantification of the
average number of Ki67+ cells per crypt over 50 crypts per section in n=5-7 mice per
group. (E) Representative Alcian Blue staining in proximal intestinal crypts from Nt+/+ and
Nt-/- mice fed either AL or fasted for 48 h. (F) Quantification of the percentage of Alcian
Blue+ cells per crypt over 50 crypts per section in n= 6 mice per group. (G) Representative
western blot analysis of total GSK3β in crypts from Nt+/+ and Nt-/- mice fed either AL or
fasted for 48 h. n=3 mice per group are shown. (H) Densitometry analysis was performed
to quantify total GSK3β expression relative to Actin in n=5 mice per group. (I) NTR1
mRNA expression in indicated tissues. (J) Lgr5-GFP+ ISC frequency in freshly isolated
crypts from Nt+/+ and Nt-/- mice fed either AL or fasted for 48 h. N=4 mice per group. (K)
Enrichment plots generated by GSEA for Fatty Acid Metabolism and PPARδ signaling
gene sets based on RNAseq data from crypts isolated from Nt+/+ and Nt-/- mice fed AL or
fasted for 48 h. NES, normalized enrichment score relative to Nt+/+ groups. q, Falsediscovery rate (FDR)-adjusted p-value. (L) qRT-PCR analysis of Cpt1a and Hmgcs2
mRNA expression in RNA from intestinal crypts isolated from Nt+/+ and Nt-/- mice fed
either ad libitum (AL) or fasted for 48 h. n= 5-7 mice per group. Data shown are
means ± standard deviation (SD). Significant differences are shown with asterisks. *P <
0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; , not statistically significant. Scale bars
indicate 50 µM).
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS
Neurotensin is a trophic hormone that promotes proliferation of the intestinal
mucosa and several types of cancer cells (31, 48, 89). In this study, we investigated 1) the
mechanisms regulating NT release from endocrine cells and methods for modulating NT
secretion, 2) the role of NT on proliferation and stem cell function in the normal small
intestine and 3) the impact of NT on stem cell function in CRC. These studies provide
greater mechanistic and functional insight into the processes controlling NT secretion and
its physiological and pathological effects in the intestine.
NT is released from EE cells, a rare population of differentiated epithelial cells in
the small intestine that secrete gut peptides (35). Multiple sub-populations of EE cells exist
that predominantly secrete only specific gut peptides, with the NT-specific EE cell
traditionally referred to as N-cells (34, 86). Thus, isolating and culturing the NT-secreting
cells for mechanistic studies is complicated by the rarity of the cell population in addition
to the low fidelity of normal epithelial cell cultures (180). To overcome these limitations,
we utilized two endocrine tumor cells lines that release NT in a manner analogous to that
of N-cells (181, 182). Our findings demonstrate that FFA-stimulated NT release from
endocrine cells is positively regulated by the RAF-MEK-ERK scaffold protein KSR1, and
that NT release can be controlled via modulation of KSR1 expression or the activity of
MEK or ERK in the MAPK signaling pathway. Furthermore, we identify a novel role for
the exocyst complex component Exo70 in regulation of NT release and ERK1/2 signaling.
Given the dichotomous role of NT, understanding the mechanisms controlling NT release
will provide greater insight into how NT may be used therapeutically. The role of NT on
intestinal lipid absorption and metabolic dysfunction makes NT a particularly attractive
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target for the treatment of obesity associated metabolic disorders. Our findings identify a
novel role for KSR1 and Exo70 in regulation of NT expression and secretion, suggesting
that these proteins may have therapeutic potential in the treatment of NT-driven metabolic
disorders.
A major goal of this study was to further our understanding of the trophic effects
of NT in the small intestine. Most recent studies investigating the proliferative role of NT
have been carried out in cancer cells (48). Though early in vivo studies using rat models of
intestinal resection or nutrient deprivation identified the trophic function of NT in the
intestine, the relative difficulty of culturing normal intestinal epithelial cells in vitro has
limited investigations into the molecular mechanisms regulating NT-induced growth in the
intestine (40, 41, 74, 180, 183). The establishment of ISC-derived organoid models
provides a powerful method for studying normal intestinal physiology in vitro, and
methods for effective isolation of whole intestinal crypts enables rapid analysis of in vivo
signaling relative to histological analysis (184). Using these state-of-the-art methods, we
were able to gain greater insight into the functions of NT in the normal small intestine
under physiological conditions.
We demonstrated that NT plays an important role in regulation of the cell cycle,
crypt progenitor cell proliferation, and positive regulation of the ERK1/2 signaling
pathway, providing greater insight into the mechanisms underlying the trophic effects of
NT in the small intestine. In addition, this study is the first to identify a role for NT in
regulation of ISC function. Our findings demonstrate that the functional consequences of
NT in the small intestine are dependent on nutrient status, implicating NT as an important
link between nutrient-sensing pathways and intestinal homeostasis. While NT appears to
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predominantly regulate cell proliferation via ERK1/2 and cyclin D1 expression during
nutrient-rich conditions, nutrient depletion switches the effects of NT from maintenance of
cell proliferation to maintenance of ISC integrity. Under stress conditions, in which too
few nutrients are available for normal levels of cell proliferation, NT increases WNT/bcatenin signaling and promotes an ISC gene expression signature, leading to enhanced ISC
function. Moreover, we find that the function of NT on ISCs is conserved in Drosophila
during nutrient-depletion, suggesting that NT plays an important role in preservation of
ISC integrity during intestinal stress in order to prevent irreparable crypt loss and mucosal
damage. This is consistent with the similar effects of GLP-2, which maintains crypt cell
proliferation during TPN via activation of WNT/b-catenin signaling (168). Like GLP-2,
NT is an attractive therapeutic target for promoting mucosal cell growth during periods of
nutrient-depletion, inflammation, or mechanical damage (72, 73, 75). Our findings provide
greater insight into the mechanisms by which NT promotes mucosal growth and identifies
a novel role for NT in ISC function, thus expanding the potential clinical applications of
NT.
The effects of NT on ISC function led us to interrogate the role of NT on CSC
function. While our findings suggest that NT confers enhanced CSC function in multiple
CRC cell lines, many additional questions remain regarding the full extent of NT on tumor
initiation and CSC function. The next steps in fully characterizing the contribution of NT
in CRC stem cell function and tumor growth is a comprehensive study of the effects of NT
deficiency in mouse models of CRC. Our APCmin tumor organoid model has yielded
promising preliminary data suggesting that NT promotes tumor stem cell clonogenicity,
and our survival analysis thus far indicates that loss of NT significantly increases survival
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in APC mutant mice. However, the extent to which NT regulates tumor number, size, or
progression remains to be seen. Mechanistically, these studies show that the effects of NT
on ISC function and CSC function are mediated by positive regulation of WNT/b-catenin
signaling. Thus, as in many other systems, WNT activation downstream of NT/NTR1
signaling has positive and negative benefits depending on cell type. The role of NT on
WNT/b-catenin signaling and ISC function during nutritional stress indicates that NT has
a beneficial role on ISC maintenance and crypt integrity under conditions of low nutrient
availability. In contrast, in highly proliferative CRC cells, NT-mediated WNT activation
exacerbates the effects of aberrant cell proliferation and tumor cell clonogenicity. Thus,
like WNT/b-catenin signaling, NT signaling should be tightly controlled to maintain
normal ISC physiology without contributing to aberrant cell growth and tumor progression.
Given the role of NT in promoting HFD-induced obesity (42) and the known stimulatory
effects of HFD on WNT/b-catenin signaling and intestinal tumorigenesis (25), it is
interesting to speculate that NT may promote HFD-induced CRC. An exciting future
experiment to address this could examine the effect of feeding a HFD in our APCmin NT+/+
and APCmin NT-/- mouse models to determine whether NT-/- is protective against HFDinduced tumorigenesis.
Regulation of ERK1/2 signaling is a persistent theme in our studies of NT release
and function. Previous work from our lab showed that NT gene expression and secretion
is enhanced by ERK1/2 signaling (44), and the present study shows that NT/NTR1
signaling activates ERK1/2 signaling in intestinal crypts and tumor organoids, leading to
enhanced proliferation and CSC function, respectively. These findings suggest that NT and
ERK1/2 may be involved in a positive feedback loop that sustains NT gene expression and
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secretion and enhances the mitogenic effects of ERK1/2-dependent functions. In intestinal
epithelial cells, this may serve as a positive signal indicating a nutrient-rich environment
suitable for rapid cell proliferation, wherein nutrient-intake activates ERK1/2 in EE cells
leading to NT release, which then binds to NTR1 and activates ERK1/2 signaling in crypt
epithelial cells, promoting cell proliferation. However, in cancer cells that release NT and
also express NTR1, the autocrine effects of NT may activate a positive feedback loop that
constitutively activates ERK1/2 signaling and leads to sustained cell proliferation and
enhanced tumor growth and disease progression. Thus, KSR1 and Exo70 may be useful
therapeutic targets for controlling NT release and excessive ERK1/2 activation in cancer
cells. Future studies that examine whether KSR1 or Exo70 manipulation alter the effects
of NT on CRC cells or ISCs will be needed to determine their full therapeutic potential.
Notably, the effects of endogenous NT on proliferation and ISC function were
greatest in the distal small intestine, where NT expression and secretion is highest (33).
That NT regulates proliferation and ISC function primarily in the crypts closest to the site
of NT release suggests that these functions occur in a paracrine manner. A major question
still remaining to be addressed is whether NT regulates ISC function directly or indirectly.
NTR1 expression is largely undetectable in normal intestinal epithelial cells (30, 52), yet
we find that NT elicits robust effects on cell proliferation, ISC function, and ERK1/2, and
WNT/b-catenin signaling. To address the question of NTR1 localization, we examined
NTR1 mRNA expression and showed that NTR1 is not expressed in intestinal crypts, villi,
or mucosal scrapings, but we did detect NTR1 expression in full-thickness small intestine,
which includes the mucosa and submucosa. Notably, subepithelial fibroblasts and the
mesenchymal cells located beneath the crypt layer have recently been identified as an

101

important source WNT ligands and other ISC niche signals that support ISC function (134).
It is interesting to speculate that NT may mediate its effects on WNT/b-catenin signaling
and ISC function by regulating WNT ligand secretion from subepithelial fibroblasts.
However, future studies are needed to conclusively identify NTR1-expressing cells in the
small intestine. Isolation and culture of subepithelial fibroblasts from the small intestine
may represent a critical experiment for determining whether NTR1 is expressed in this cell
population and, if so, whether NT impacts secretion of ISC niche factors.
In conclusion, this study identifies a novel role for NT as a regulator of stem cell
function and WNT/b-catenin signaling in the normal small intestine and in CRC.
Moreover, we identify KSR1, a molecular scaffold of the RAS/RAF/ERK pathway, and
Exo70, a mediator of exocytosis, as potential therapeutic targets for modifying NT release
(Fig 5.1). Collectively, these studies reveal a new function of NT as a regulator of ISC and
CSC function and identify clinically-relevant targets for regulating NT-mediated effects in
the normal intestine and in intestinal tumors.
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Figure 5.1. Mechanisms regulating NT release and function in the small intestine and
CRC cells. Release of NT from endocrine cells is stimulated by KSR1 and Exo70 and
attenuated by inhibition of KSR1, MEK, ERK1/2, or Exo70. Functions of NT described in
this study include regulation of proliferation and differentiation in crypt epithelial cells via
activation of ERK1/2 and cyclin D1, stimulation of ISC self-renewal during nutrientdeprivation via activation of WNT/b-catenin and Lgr5 mRNA expression in ISCs, and
enhanced WNT/b-catenin signaling and CSC self-renewal in CRC cells through
phosphorylation of LRP6 by ERK1/2.
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